CV Levin.Pdf

CURRICULUM VITAE

NAME: Frances Rudnick Levin, M.D.

CURRENT POSITION: Kennedy-Leavy Professor of Psychiatry at Columbia University Medical Center Associate Attending of Psychiatry New York Presbyterian Hospital Chief, Division on Substance Abuse at Columbia University/New York State Psychiatric Institute (NYSPI)

WORK ADDRESS: NYSPI/Department of Psychiatry 1051 Riverside Drive, Unit 66 New York, NY 10032 Telephone: 212-543-5896

HOME ADDRESS: 640 Pomander Walk Teaneck, NJ 07666 Telephone: 201-836-4219

PLACE OF BIRTH: Newton, MA

MARITAL STATUS: Married - Howard Robert Levin, M.D. Founder, Coridea, Inc Founder, Cibiem, Inc.

CHILDREN: Allison Paula, October 11, 1991 Tamara Stephanie, March 31, 1995 Charles Jacob, March 31, 1995

EDUCATION:

1974-1977 Newton South High School Newton, MA

1977-1981 Brown University Providence, RI B.S. - Magna Cum Laude with Honors

1981-1985 Cornell University Medical College New York, NY M.D.

1985-1989 Resident in Psychiatry The New York Hospital, Payne Whitney Clinic New York, NY

1988-1989 The New York Hospital, Payne Whitney Clinic New York, NY Assistant Unit Chief

1989-1990 National Institute on Drug Abuse and University of Maryland Baltimore, MD Research and Addiction Psychiatry Fellow

ACADEMIC APPOINTMENTS:

University of Maryland Medical Center, Department of Psychiatry

1990-1992 Assistant Professor

Columbia University College of Physicians and Surgeons, Department of Psychiatry

1992-1999 Assistant Professor of Clinical Psychiatry 1999- 2006 Q.J. Kennedy Associate Professor of Clinical Psychiatry 2006-2013 Kennedy-Leavy Professor of Clinical Psychiatry 2013-present Kennedy-Leavy Professor of Psychiatry at Columbia University Medical Center

HOSPITAL TITLES:

University of Maryland Medical Center

1990-1992 Assistant Attending Psychiatrist

New York-Presbyterian Hospital

1992-1999 Assistant Attending Psychiatrist 1999-present Associate Attending Psychiatrist 2006- Attending Psychiatrist

ADMINISTRATIVE POSITIONS:

1990-1991 Medical Director Alcohol and Drug Clinic University of Maryland Baltimore, MD

1990-1992 Consultant National Institute on Drug Abuse Addiction Research Center University of Maryland Baltimore, MD

1990-1992 Director Outpatient Addiction Services, Walter P. Carter Center University of Maryland Baltimore, MD

1992- 2000 Associate Director of Substance Abuse Education

1999-present Director, Addiction Psychiatry Residency Columbia University/New York State Psychiatric Institute New York, NY

2003-present Director, Clinical and Educational Activities Division on Substance Abuse Columbia University/New York State Psychiatric Institute

HONORS RECEIVED: Phi Beta Kappa, Junior Year- 1980 Sigma Xi-1981 Magna Cum Laude (with Honors for Thesis)-1981 Connie Guion Scholarship-1983 AMA-ERF Rock Sleyster Memorial Scholarship-1985 Faculty Council Excellence in Teaching Award-1989 Travel Awardee, Committee on Problems of Drug Dependence – 1993 Chair, Q.J. Kennedy Associate Professor of Clinical Psychiatry-2001-2006 Member, National Institute on Drug Abuse (NIDA)- Initial Review Group: Training and Career Development Subcommittee-2001-2005; Reappointed 2006-2010 American Council of Graduate Medical Education-Addiction Psychiatry Board Review Committee 2000-2006 Chair, Area Directors for the American Academy of Addiction Psychiatry,-2001-2003 Board Member, American Academy of Addiction Psychiatry-2001-present Treasurer, American Academy of Addiction Psychiatry- 2004-2008 Best Doctors in America- 2002-2003, 2007-2010, 2013 Fellow, American Psychiatric Association- 2003 America’s Top Psychiatrist 2004-2008 Chair, Kennedy-Leavy Professor of Clinical Psychiatry- 2006- Council of Addiction Psychiatry, American Psychiatric Association 2007-2009 Who’s Who In America- 60th Anniversary, 2006, 2008-2015 Best Doctors® in America, 2002-2010, 2013 Board of Directors, Group for the Advancement of Psychiatry, 2007-2009 New York Top Doctor, 2007, 2008, 2015 Vice President, American Academy of Addiction Psychiatry- 2007-2009 Top Doctor: New York Metro Area, 2009, 2011-2015 Chair, Women’s Initiatives in Psychiatry for Dept. of Psychiatry/Columbia University 2009- President-Elect, American Academy of Addiction Psychiatry 2009-2011 Member, CPDD Credentials Committee, 2009-2012 Member, APA Program Committee, 2010-2012 President, American Academy of Addiction Psychiatry 2011-2013 Who’s Who in the World, 2011, 2012 Who’s Who of American Women, 2011-2013 Who’s Who in Science and Engineering, 2011-2013 Who’s Who in Medicine and Healthcare, 2011-2013 Best Doctors, New York Magazine, June, 2011-2015 US News Top Doctor, 2012-2015 Irving Institute (CSTA) Mentor Award, Honorable Mention, 2012 Chair, Data and Safety Monitoring Board, P50 Center for University of Minnesota, 2012-2017 Chair, APA Council on Addiction, 2013-2017

Marquis Who’s Who, 2013 Member, National Association of Profession Women (NAPW), 2013 Global Who’s Who, 2013 Founders Award, American Academy of Addiction Psychiatry, 2015 Distinguished Fellowship, American Psychiatric Association, 2015

PROFESSIONAL CERTIFICATIONS:

Diplomate, American Board of Psychiatry and Neurology - 1990 Certified in Addiction Medicine (ASAM) - 1991 Added Qualifications in Addiction Psychiatry, American Board of Psychiatry and Neurology – 1993 Recertification Added Qualifications in Addiction Psychiatry, American Board of Psychiatry and Neurology- 2002 to 2013, 2013-2023 (Certificate #243)

MEMBERSHIP IN PROFESSIONAL ORGANIZATIONS:

1981 American Medical Association 1985 American Psychiatric Association 1989 American Academy of Addiction Psychiatrists 1989 Maryland Psychiatric Society 1989 Member - Committee on Addiction, Maryland Psychiatric Society 1989 Association for Medical Edmetroucation and Research in Substance Abuse 1989 American Society of Addiction Medicine 1991 Member - Northeast Region Subcommittee on Fellowships for American Society of Addiction Medicine 1993 Regular Member - College on Problems of Drug Dependence 1993 Member - Substance Abuse Steering Committee for the Medical School Curriculum, Columbia University 1993 Member - Curriculum Committee for Hazelden Fellowship Club's Physicians in Residence Program 1995 Member- Fellowship Committee for the American Academy of Addiction Psychiatrist 1996 Member- Program Committee for Annual Meeting for the American Academy of Addiction Psychiatrists 1998 Fellow, The New York Academy of Medicine 2007-2009 Member, Group for the Advance of Psychiatry (GAP) 2013-2015 Member, Group for the Advancement of Psychiatry (GAP) 2007 New York Psychiatric Society 2010 Member, American Professional Society of ADHD and Related Disorders (APSARD) Program Committee 2010 Member, Advancing the Practice of Addiction Medicine (ABAM) 2010 Member, National Addiction Medicine Residency Assistance Council (NAMRAC) 2010 Member, American Board of Addiction Medicine Foundation’s Training and Accreditation Committee

Current Journal Reviewer for: Addictions, American Journal of Psychiatry, American Journal on Addictions, Current Psychiatry, Drug and Alcohol Dependence, Substance Abuse, Journal of Substance Abuse, Practical Psychiatry and Behavioral Health, Journal of Experimental and Clinical Psychopharmacology, Journal of Addiction Medicine, Journal of the American Medical

Association, Journal of Attentive Disorders, Journal of Clinical Psychiatry, Journal of Clinical, Lancet Psychiatry, Psychopharmacology

Editorial Board Member: American Journal on Addictions, Journal of ADHD, Journal of Substance Abuse & Alcoholism, Open Addiction Journal, and Journal of Addiction and Prevention, Section Editor, Section on Substance Use and Related Disorders, Current Psychiatry Reports published by Springer

Dissertation Examiner for: Madeline Rhum, PhD. candidate in Clinical Psychology. Dissertation Topic “Effects of personality disorder on treatment response and outcome in cocaine-dependent outpatients.”

Guert van de Glind, PhD, candidate in Clinical Psychology. Dissertation Topic: “ADHD and Substance Use Disorder,” October 22, 2013.

INVITED EXTERNAL AND UNIVERSITY COMMITTEES:

1992 Facilitator and Panel Member, Federal Resource Panel - Treatment Improvement Protocol (TIP) on "Screening, assessment, and treatment planning for patients with dual dependency on narcotics and stimulants."

1993-2000 Member, Assistance to Impaired Medical Students

1994 Committee on Alternative Medicine, Office of Mental Health, New York State

1994 Expert Field Reviewer - Treatment Improvement Manual (TIP) on "Meeting patient needs in opioid substitution therapy: matching patients to treatment services."

1994 Curriculum and Review and Development in Medicine Subcommittee for the Addiction Training Center, New York State Office of Alcoholism and Substance Abuse Services.

1994-95 Office of Alcoholism and Substance Abuse Services (OASAS) LAAM Advisory Group

1995 Ad-Hoc Committee to Review Women's Health Issues in the Columbia University Medical School Curriculum

1995 Scientific Advisory Committee to Hazelden Treatment Programs

1995-2000 Doctors' Offices Committee - Columbia/Presbyterian Committee to examine issues related to professional practices within the medical center

1995 Invited Working Conference. Improving Services: Co-Occurring Mental Health and Substance Abuse Disorders. Substance Abuse and Mental Health Services Administration (SAMHSA). November 14, 1995, Washington, D.C.

1995- Fellowship Committee- American Academy of Psychiatrists in Alcoholism and Addictions

1996-1999 Nominating Committee- American Academy of Addiction Psychiatry 5

1996-2001 New York Area II Director for the American Academy of Addiction Psychiatrists

1996 Facilitator and Panel Member - Treatment Improvement Protocol (TIP) on "Treatment of Stimulant Abuse."

1997-2000 Faculty Chairman- Assistance to Impaired Medical Students, Columbia University

1997-2001 Chairman- Program Committee for Annual Meeting for the American Academy of Addiction Psychiatrists (Chairman 1999-2001)

1998 Consultant, OASAS-sponsored Committee to Assess Training/Develop Credentials for a Substance Abuse Clinician

1999-2001 Committee for Subspecialty of Addiction Psychiatry, American Board of Psychiatry and Neurology, Member

2000-2001 Member, Assistant to Impaired Medical Students

2001-2003 Member, Committee on Addiction Psychiatry, American Psychiatric Association

2001- Member, Program Committee for American Academy of Addiction Psychiatry

2001- Member, PGY5 Committee for American Academy of Addiction Psychiatry

2001-2003 Chair, Area Directors for the American Academy of Addiction Psychiatry

2001-2005 Member, National Institute on Drug Abuse (NIDA)-K Review Committee

2002-2003 Member, APA, Committee on Addiction Psychiatry-NY District Branch

2002-2006 Member, APA Committee on Training and Education in Addiction Psychiatry

2006-2010 Reappointed – Member, National on Drug Abuse (NIDA)-K Review Committee

2007- 2009 APA Council on Addiction Psychiatry, Member

2007- Executive Committee to the Faculty Council, Columbia, University, Member

2007- Faculty Council Member for Columbia University

2008- Member, Department of Psychiatry, Committee on Appointments (COAP)

2007- 2008 Medical Student Curriculum Committee for Department of Psychiatry, Columbia University

2007- Resident Advisor to Psychiatry Residents (PGYI, PGYII, PGYIII)

2007- 2008 Search Committee for Chairman of Geriatric Psychiatry, New York State Psychiatric

2008- Member, Pharmacy and Therapeutics Committee for New York State Psychiatric Institute

2008 Member, Psychiatric Residency Curriculum Evaluation Committee

2008- Member, Marketing and Communication Work Group for New York State Psychiatry Institute/Columbia University

2008- Interviewer for Psychiatry Residency Candidates for NY Presbyterian Hospital/Columbia University

2009- Member, Ethics Advisory Committee for NYSPI

2010- Member, American Professional Society of ADHD and Related Disorders (APSARD) Program Committee

2010-2011 Consultant, American Psychiatry Association Scientific Program Committee

2010- Medical Student Candidate Interviewer- Admissions Committee, Columbia University Medical School

2010, 2015 Member, AACAP Physician Scientist Program in Substance – K12 Advisory Committee

2011-2014 Member, Governance Committee, Research Foundation for Mental Hygiene (RFMH)

2011-2014 Board of Director, Research Foundation for Mental Hygiene (RFMH)

2012 Search Committee for Chairman of Biostatisics, New York State Psychiatric Institute

2011 Reviewer, ZDA1 EXL – P50 Centers of Excellence Review Committee (NIDA), February 22-23, 2011

2011 Peer Review Committee, New York State Psychiatric Institute (NYSPI)

2012-2014 Reviewer, RPIA-N – Risk Prevention and Intervention for Addictions (NIDA), February 23-24, 2012, October 24, 2012, March 1, 2013, June 10-11, 2013, March 3-4, 2014

2013 Residency Evaluation Committee

2015-2016 Reviewer, RPIA-IPTA – Risk Prevention and Intervention for Addictions (NIDA), October 8-9, 2015

2015 Chair, Data and Safety Monitoring Committee, New York State Psychiatry Institute (NYSPI)

2015 Chair, DSMB – University Minnesota SCOR Project: Sex Differences and Progesterone Effects on Impulsivity, Smoking & Cocaine Abuse

TEACHING EXPERIENCE:

1988 Case Supervision, Second Year Psychiatric Residents and Certified Mental Health Social Workers, Payne-Whitney Clinic, The New York Hospital.

1990-1991 Course Director, Substance Use Disorders in Psychiatric Practice for Fourth Year Psychiatric Residents, University of Maryland.

1990-1992 Course Director, Diagnosis and Treatment of Adolescent Substance Abusers for Child Fellows, University of Maryland.

1990-1992 Supervision of Drug/Alcohol Counselors and Certified Mental Health Social Workers.

1991 Course Director, Topics in Substance Abuse for Third Year Psychiatric Residents, University of Maryland.

1992 Course Director, Topics in Substance Abuse for First Year Psychiatric Residents, University of Maryland.

1993 Panelist for Post-Interdisciplinary Day on Substance Abuse for First Year Medical Students, Columbia University/New York State Psychiatric Institute.

1993 Coordinator, Substance Abuse Lectures for Psychiatric Residents, Middletown Hospital Residency Program.

1993 Lecturer, Primary Substance Abuse Elective.

1993-2004 Co-Director, Substance Abuse Research Fellowship

1993- present Course Director, Substance Abuse Seminar for Second and Third Year Psychiatric Residents, Columbia University/New York State Psychiatric Institute.

1993-2001 Coordinator, Substance Abuse Lectures for Internal Medicine Housestaff.

1993-2003 Curriculum Committee Member and Lecturer for Hazelden Club's Physician in Residence Program.

1993- 2009 Coordinator, Substance Abuse Curriculum for Clinical Practice Course for First and Second Year Medical Students.

1993- 2009 Coordinator, Substance Abuse Module and Case Conference for Pharmacology Course for Second Year Medical Students.

1994- present Supervisor, Third Year Psychiatry Residents for Substance Abuse Cases 8

1998-present Coordinator, Substance Abuse Seminars for PGY-II and PGY-III Psychiatry Residents

1998-present Director, Addiction Psychiatry Residency Program of NY Presbyterian Hospital

2001-2004 Coordinator and Lecturer, Hazelden Lectures for Internal Medicine Housestaff

2004-present Director, Substance Abuse Research Fellowship

2005-present Coordinator, Substance Abuse Rotation for PGY-III Psychiatry Residents

2009 Course Director, CME Course sponsored by Columbia University: Intervention for Substance Abuse: Modern Research and Its Practical Application Applications

2010- present Coordinator, Substance Abuse Curriculum for Neuroscience Course for first/second year medical students

2010-present Coordinator, Substance Abuse Curriculum for Fundamentals in Medicine Course for first/second year medical students

GRANT SUPPORT:

1993-1998 Co-Investigator, National Institute on Drug Abuse, (R01 DA006234), “Intravenous Cocaine Abuse Treatment: A Laboratory Model”, Principal Investigator, R. Foltin, TDC: $1,819,812.

1993-2004 Co-Principal Investigator, National Institute on Drug Abuse, T32 DA007294, Research Fellowship in Substance Abuse Disorders, TDC: $1,106,140.

1994-1996 Principal Investigator, New York State Psychiatric Institute Research Studies Grant, "Flupenthixol Treatment for Dually-Diagnosed Populations." TDC: $6,100.

1994-1996 Principal Investigator, Columbia University, Office of Clinical Trials, Pilot Study Award, "Flupenthixol, Utility for Schizophrenic Cocaine Abusers." TDC: $50,000.

1994-1996 Co-Principal Investigator, NIDA Grant No. R01 DA08650, "Treatment of Cocaine Abuse and Attention Deficit Disorder" Principal Investigator: Herbert D. Kleber, TDC: $1,183.017.

1994-1999 Principal Investigator*, Scientist Development Award for Clinicians, Grant No. K20 DA00214, "Treatment of Cocaine Abuse and Psychiatric Comorbidity." TDC: $709,676.

1994-1999 Medical Director, Grant No. P50 DA09236, "Novel Medication Approaches for Substance Abuse" Principal Investigator: Herbert D. Kleber TDC: $4,980,474.

1995-2000 Co-Principal Investigator, Grant No.RO1 DA09114,“Vulnerability to Anxiolytic Abuse in Woman. Principal Investigator, Suzette Evans, Ph.D. TDC: $1,915,518.

1996-1999 Co-Investigator, PTSD Treatment Outcomes for Cocaine-Dependent Women, Principal Investigator, Denise Hien, Ph.D. TDC: $237,397.

1998-2003 Principal Investigator*, Grant No. R01 DA 11444, “Treatment of Adult ADHD in Methadone Patients.” TDC: $1,765,995.

1998-2004 Principal Investigator, Grant No R01 DA 11755, “Methylphenidate Treatment for Cocaine Abuse and ADHD.” TDC: $1,417,841.

1994-1999 Co-Principal Investigator, Grant No. P50 DA 09236, "Novel Medication Approaches for Substance Abuse" Principal Investigator: Herbert D. Kleber TDC: $6,973,489.

1993-2015 Principal Investigator, Grant No. T32 Research Fellowship in Substance Abuse Disorders.; TDC: $3,064,861. (Become PI in 2004)

1999 Co-Principal Investigator, Conference Grant DA12446, “Drug Addiction Treatment: new Research Findings On-Line. Principal Investigator: Steven Hyler

1999-2003 Principal Investigator, Supplement to a NIDA-funded grant (DA 11755): “HIV Counseling Intervention for Methadone-Maintained Patients.”; TCD:$170,96

1999-2005 Principal Investigator, P50 DA12761. “Novel Pharmacotherapies for Cocaine Dependence Center, TDC: $3,928,382. (Dr. Fischman was PI from 1999-2001; after her death Dr. Levin become PI from 2001-2005)

1999-2003 Preceptor, Grant No. K23 DA00433, Opiate and Nicotine Dependence: Medications and Therapy; Principal Investigator: Maria Sullivan, M.D., Ph.D., TDC: $725,125.

2000-2004 Sponsor, APSYA CU514905- American Psychiatric Association- NIDA. Cocaine Abuse and/or Schizophrenia: Integrated Treatment. Principal Investigator Evaristo Akerele.

2000-2005 Principal Investigator, Grant No. DA00465 K02 Independent Scientist Award, “Treatment of Substance Abuse and Psychiatric Comorbidity” TDC: $563,650.

2000-2004 Co-Principal Investigator, Grant No. RO1 DA13191 “Marijuana Pharmacotherapies: Controlled Clinical Trials”, Principal Investigator, David McDowell, M.D. TDC: $1,132,363.

2000-2005 Co-Principal Investigator, Grant No. RO1 DA09114, “Vulnerability to Anxiolytic Abuse in Woman. Principal Investigator, Suzette Evans, Ph.D. TDC: $ 1,621,946.

2000-2010 Co-Principal Investigator, Grant No. RO1 DA09114, Vulnerability to Anxiolytic Abuse in Woman. Principal Investigator, Suzette Evans, Ph.D. TDC: $1,621,946.

2001-2002 Principal Investigator: Eli Lilly Co, “Olanzapine treatment of marijuana and/or cocaine abuse among schizophrenic substance abusers using marijuana and cocaine”. TDC: $227,119.

2001-2006 Co-Investigator, Director of Treatment Training Unit, Clinical Trials Network, Grant No. U10 DA13035, “CU Partners: NY/Long Island Regional Node, Principal Investigator, Edward V Nunes, M.D. TDC: $5,142,976.

2000-2005 Principal Investigator, NARSAD Independent Investigator Award, Olanzapine treatment of marijuana and cocaine abuse in schizophrenic substance abusers TDC: $92,578.

2003 Site Principal Investigator, Pharmaceutical Company initiated protocol. OrthoMcNeil, Topiramate treatment for alcohol dependence, TDC: $219,400.

2003 Principal Investigator, Investigator-initiated protocol, Leviteracitam treatment for anxious alcoholics, TDC $82,253

2003 (Site) Principal Investigator Pharmaceutical Company initiated protocol. AstraZeneca Pharmaceuticals, A Multi-center, Randomized, Parallel-group, Double-Blind, Phase IV Comparison of the Efficacy of Quetiapine Fumarate to Placebo in the Treatment of Bipolar I Disorder and Alcohol Dependence, TDC: $13,500.

2003-2008 Preceptor, Grant No. K23 DA016743 Cognition in Cocaine Dependence: Assessment & Therapy, Principal Investigator, Efrat Aharonovich, PhD. TDC: $819,700.

2003-2008 Co-Investigator, Grant No. RO1 DA006234 Cocaine Abuse Treatment: A Laboratory Model, Principal Investigator, Richard Foltin, TDC: $1,819,812.

2003-2006 Co-Principal Investigator, Grant No. R03 DA015559, Screening for Comorbidity in Substance Abuse Clinics, Carlos Blanco, MD, TDC: $150,000.

2003-2008 Principal Investigator, Grant No. RO1 DA 015451 Marijuana dependence and depression: venlafaxine treatment, TDC: $1,938,983.

2004 Principal Investigator, UCB Pharma, (4474) Levetiracetam Treatment for Anxious Alcoholic, TDC: $83,753

2004-2007 Principal Investigator, Grant No. R01 DA019233, Marijuana abusing ADHD teens: Atomoxetine treatment, TDC: $85,801

2004-2007 Site Principal Investigator, OrthMcNeil (CAPSS 278) Topiramate Treatment for Alcohol Dependence, TDC: $219,000

2004-2009 Principal Investigator, Grant No .P50 DA09236 (Center PI: Dr. Herbert Kleber) Agonist treatment for marijuana dependence, TDC: $871,699.

2005 Investigator, Pharmaceutical Company initiated protocol. SHIRE Pharmaceuticals, Prevention of Adolescent Substance Use with Adderall XR

Treatment of ADHD. Principal Investigator: Jeffrey Wilson, MD, TDC: $97,575.

2005-2010 Co-Principal Investigator, Grant No. R01 DA009114, Combined Treatment of Alcohol-Dependent Women with PTSD. Principal Investigator: Denise Hien, Ph.D. TDC: $2,322,046.

2005-2010 Principal Investigator, Grant No. K02 DA00465, Treatment of Substance Abuse and Psychiatric Comorbidity, TDC: $614,304.

2005-2010 Primary Mentor, Grant No. K23 DA020000, Buprenorphine for Opioid Dependence in Primary Care, Principal Investigator, Erik Gunderson, MD, TDC: $818,000.

2005-2010 Primary Mentor, Grant No. K23 PA00004, Anticonvulsant Pharmacotherapy for Sedative Hypnotic Use Disorder, Principal Investigator, John Mariani, MD, TDC: $883,684.

2006-2010 Principal Investigator, Grant No. R01 DA022217, Combined Pharmacotherapies for Cocaine Dependence, TDC: $750,000.

2007-2013 Principal Investigator, Grant No. R0 DA023652, Extended Release of Mixed Amphetamine Salts for Adult ADHD and Cocaine Dependence, TDC $1,545,769.

2009-2013 Principal Investigator, Grant No. R01 DA026250 – Multi-Site Controlled Trial of Cocaine Vaccine TDC $ 1,053.413.

2009-2014 Principal Investigator, Grant No .P50 DA09236 (Center PI: Dr. Herbert Kleber) Combined Pharmacotherapies for marijuana dependence, TDC: $1,335,959.

2009-2014 Co-mentor, Grant No. K23 DA025735, Glutamatergic Modulation of Exposure Therapy in Cigarette Smoking, Principal Investigator, S. Rob Vorel, MD, TDC: $825,560.

2009-2014 Co-mentor, Grant No. K23 DA027044, Mifepristone Treatment of Cocaine Dependence, Principal Investigator, Wilfrid Raby, MD, TDC, $862,200.

2010-2012 Co-Investigator, Grant No. R21 AAA017691, Gabapentin for Abstinence Initiation in Alcohol Dependence, Principal Investigator, John Mariani, MD, TDC, $239,850

2010-2014 Co-mentor, Grant No. K12 DA000357, Neural correlates of Multiple Learning and Memory System in Adolescent Cannabis Users, Principal Investigator, Gregory Tau, MD, TDC, $548,800.

2010-2015 Principal Investigator, Grant No. K24 DA029647, Substance Abuse Treatment Development and Clinical Research Mentoring, TDC $891,535.

2010-2015 Co-mentor, Grant No. K01 DA029598, Prenatal Smoke Exposure and Offspring Substance Use: An Imaging-Genetics Approach. Principal Investigator, A. Talati, MD, TDC $824,500. 12

2010-2015 Co-Mentor: Grant No. K02 DA026538, Integrated Family-Based Treatment of Co-occurring Adolescent SUD and ADHD, Principal Investigator, A. Hogue, PhD, TDC $625,750

2011-2016 Primary Mentor, Grant No. K23 DA031771, Brief Potent Glutamatergic Modulation: Applications for Cocaine Dependence, Principal Investigator, E. Dakwar, MD, TDC $862,000.

2012-2017 Principal Investigator: Grant No. R13 DA015108, Conference Grant, American Academy of Addiction Psychiatry 23-27th Annual Meeting and Symposium, TDC $375,000.

2012-2016 Co-Investigator: Grant No. R01 DA031826, Quetiapine Pharmacotherapy for Cannabis Dependence, Principal Investigator, J. Mariani, MD, TDC: $1,530,780

2012-2014 Principal Investigator: Grant No. NIDA/VA CS103, Nepicastat for Cocaine Dependence, TDC $643,232

2013-2016 Principal Investigator: Grant No. U01 DA033310, ½ Multicenter Trial of Combined Pharmacology to Treat Cocaine Dependence, TDC $1,372,962

2013-2015 Co-Investigator: Grant No. R21 DA035472, The effect of Glutamateric Modulation on Cocaine Self-Administration, Principal Investigator, E. Dakwar; TDC $363,750

2013-2016 Significant Contributor. Grant No. R21 DA034858, Gabapentin Treatment of Benzodiazepine Dependence, Principal Investigator, J. Mariani; TDC $250,000

2013-2016 Principal Investigator: Grant No. R18 HS021962, Advancing Patient-Centered Outcomes in Addiction Psychiatry Practice, TDC $278,461

2013-2016 Medical Director: Substance Abuse and Mental Health Services Administration (SAMHSA), U79 T10124697, PCSS-MAT: Implementing Pharmacotherapies for Opioid Dependence: Collaborative Strategies for Training Health Professionals, Principal Investigator: Kathryn Cates-Wessel, TDC $889,173

2013-2018 Principal Investigator: Grant No. RO1 DA 034087, A Sequenced Behavioral and Medication Intervention for Cocaine Dependence, (Multiple PI with Dr. Kenneth Carpenter)TDC $2,498,270

2013-2018 Primary Mentor, K23 DA034853, “OT-Based Cognitive Rehabilitation of Cocaine Abusers”, Principal Investigator: R. Kalapatapu, TDC: $832,215. (Candidate related to California and changed Mentoring Team)

2014-2017 Medical Director: Substance Abuse and Mental Health Services Administration (SAMHSA), U79 TI025595, PCSS-O: Provider’s Clinical Support System for Opioid Therapies, Principal Investigator: Kathryn Cates-Wessel, $000,000.

2014-2019 Principal Investigator, Grant No. U54 DA037843, Shared Pharmacotherapeutic Strategies for Cannabinoid and Opioid Use Disorder, TDC: $8,431,735

2014-2019 Primary Mentor, K23 AA022771, The Role of Neural Systems for Emotion Regulation in Coping with Alcohol Craving, Principal Investigator: N. Naqvi, TDC: $862,000

2015-2016 Principal Investigator, Grant No. AZD8529, Multi-Center of AZD8529 for Smoking Cessation in Female Smokers, TDC: $408,755

2015-2018 Principal Investigator, Substance Abuse and Mental Health Services Administration (SAMHSA), Grant Number H79 T1025937, Training Medical Dental Students in SBIRT, TDC: $736,440

COMMUNITY SERVICE:

April 24, 1990 Workshop on "Clinical Approaches with the Dually-Diagnosed Adolescent," sponsored by the Health and Education Council, Inc., Timonium, MD.

May 24, 1990 Forum on "Cocaine Abuse, Science, Public Policy and the Law," presentation on "Drugs Which Reduce Cocaine Craving," University of Maryland, Baltimore, MD.

June 9, 1992 Family Preservation: Philosophy, Practice, and Resources, presentation on "Consequences of Parental Substance Abuse on Children," Maryland Department of Human Resources, Timonium, MD.

Sept. 14, 2000 Manhattan Adult Attention Deficit Disorder Support Group. “ADD and Substance Abuse,” New York City, NY.

Oct. 28, 2002 Psychopharmacology Training Program. Office of Mental Health “Psychopharmacology of Substance Abuse,” Schenectady New York.

INVITED PRESENTATIONS:

1) "Neonatal Risks of Maternal Drug Use," presented at OB/GYN Grand Rounds, University of Maryland, MD, July 1990

2) "Chemically-Dependent Women in Pregnancy," presented at OB/GYN Grand Rounds, Maryland General Hospital, MD, December 1990.

3) "Brief Psychotherapy with Substance Abusers," presented at Howard County General Hospital Psychiatric Conference, January 1991.

4) "Mother, Fetus and Addiction: A Deadly Triangle," presented at Nursing Convention: Strategies for Debate, Annual Conference, Baltimore, MD, August 21, 1992.

5) "Difficulties in Assessing the Drug Treatment Literature: Heterogeneity of Outcome Measures," presented at the National Institute on Drug Abuse, Medications Development Division, Drug Use Assessment Workshop, Bethesda, MD, October 8, 1992.

6) Medications for Substance Abuse: Where we are," presented at the Arden House Scientific Conference, Harriman, NY, November 22, 1993.

7) “MICA Workshop," presented at the Sixth Annual Office of Mental Health Research Conference, Albany, NY, December 7, 1993.

8) American Psychological Association Symposium: Drugs, Crime, and ADHD: Research and Treatment. Presentation on Epidemiology and Treatment of Cocaine Abusers with ADHD. 132nd Annual Meeting of the American Psychological Association, New York, 1995.

9) Treatment Strategies for Dual-Diagnosis People” presented at Board of Advisors Meeting, Columbia Presbyterian Department of Psychiatry, New York, October 24, 1995.

10) Assessment and Treatment of Cocaine Abusing Methadone Maintained Patients, presented at the American Methadone Treatment Association Conference, Phoenix, AZ, November 2, 1995.

11) “Adult ADHD and Cocaine Abuse: Epidemiology and Treatment, New York State Office of Mental Health Seventh Annual Research Conference, Albany, NY, December 4, 1995.

12) “Prevalence and Treatment Strategies for ADHD in Substance Abuse,” New York University Division of Alcoholism and Drug Abuse, Grand Rounds, February 5th, 1997.

13) “Diagnostic and Treatment Issues for Adult Substance Abusers with ADHD,” Manhattan VA, Department of Psychiatry, Seminar, March 5th, 1997.

14) “Treatment of cocaine and opioid addicts” Medical Outlook on Psychiatry, The Cordtlandt Group, May 1997.

15) “Diagnostic and Dosing Issues in ADHD,” Investigators Meeting- NIDA Medication Development of Methylphenidate for the Treatment of Cocaine Abuse and Adult ADHD, July, 1997.

16) “Substance Abuse in Adults with Attention Deficit Hyperactivity Disorder: Assessment and Treatment,” Carrier Foundation, Grand Rounds, July 31st, 1997.

17) “New Pharmacologic Treatments for Substance Use Disorders,” Psychiatry Update 1997 Columbia-Presbyterian Medical Center, September 27th, 1997.

18) Can Medications be Used to Treat Substance Abuse. Workshop at Arden House Scientific Conference, Harriman, NY, November 24, 1997.

19) Attention-deficit hyperactivity disorder and Substance Abuse. Program Chair at the American Academy of Addiction Psychiatry, San Antonio, TX, December 7th, 1997.

20) Substance Abusers with Adult ADHD: Diagnostic and Treatment Issues. St. Lukes- Roosevelt Hospital, Grand Rounds, June 24th, 1998.

21) “Pharmacologic Treatment of Drug Addiction”, Conference on Drug Addiction Treatment: New Research Findings. April 24th, 1999.

22) “Women and Substance Abuse: Barriers to Diagnosis and Treatment”, The Spring Event at Silver Hill Hospital: Women’s Leadership in Mental Health, May 1st, 1999.

23) “Drug Abuse Clinical Research: Where is it heading?” Technical Assistance Workshop: Drug Abuse Research Scholars Program in Psychiatry, September 23rd, 1999.

24) Diagnostic Difficulties and New Treatment Approaches for Substance Abusers with ADHD. Grand Rounds, St. Barnabas Hospital, Bronx, October 06, 1999.

25) “Treatment of Nicotine Dependence in Schizophrenic Patients” presented at the Arden House Scientific Conference, Harriman, NY, November 22, 1999.

26) Adult Attention Deficit Disorder. ASAM’s State of the Art Conference: Neuroscience, Clinical Practice and Services Research, Washington, D.C., November 6th, 1999.

27) “Treatment of Substance Abuse with Pharmacologic Agents”. Grand Rounds, Creedmoor Psychiatric Hospital, Queens Village, NY, December 9th, 1999.

28) “Pharmacologic Treatments for Alcohol and Drug Abuse” Grand Rounds, St. Vincent’s Hospital, New York, January 20th, 2000.

29) “New Pharmacologic Approaches for Substance Abuse” Grand Rounds, St. Joseph’s Medical Center, Yonkers, February 10th, 2000.

30) “ADHD and Substance Abuse” Grand Rounds, Woodhull Hospital, Psychiatry Grand Rounds, Brooklyn, September 13th, 2000.

31) “Assessment and Treatment of Adult ADHD in Substance Abusers” Central New York Addiction Conference, Syracuse, October 26th, 2000.

32) “Cocaine: Pharmacotherapies are still eluding us. What can we do currently?” presented at the Arden House Scientific Conference, Harriman, NY, November 21, 2000.

33) “Adult ADHD and Substance Abuse: Diagnostic and Treatment Issues. New York State Office of Mental Health 13th Annual Research Conference, Albany, NY, December 5, 2000.

34) Substance Abuse and Adult ADHD: Diagnostic and Treatment Issues” An update on addictive disorders, comorbidity, aggressions and suicide for the practicing clinician. CME, Inc. Key West, FL, March 9th, 2001.

35) “Pharmacotherapies for Substance Dependence: Where are we?” New York State Office of Mental Health’s 14th Annual Research Conference, Albany, December 5th, 2001.

36) “Treatment for Marijuana Dependence: What does the literature tell us?” Blending Clinical Practice and Research: Forging Partnerships to Enhance Drug Addiction Treatment, National Institute on Drug Abuse, March 15th, New York, NY 2002.

37) Chair, “Marijuana Workshop”. Blending Clinical Practice and Research: Forging Partnerships to Enhance Drug Addiction Treatment, National Institute on Drug Abuse, March 15th, New York, 2002.

38) “Pharmacologic Treatment for Substance Abusers with Comorbidity: What Does the Literature Tell Us? Beth Israel Grand Rounds, Department of Psychiatry, NYC, May 9, 2002. 16

39) Substance Abuse and Psychiatric Comorbidity: Diagnostic and Treatment Issues. Brookhaven Seminar Series, July 24, 2003.

40) ADHD and Substance Abuse: Diagnostic and Treatment Approaches. Fellows Seminar, St. Louis University, Division of Psychiatric Epidemiology, St. Louis, Oct 13, 2003.

41) Substance Abuse and ADHD. Grand Rounds, St. Lukes- Roosevelt Hospital, June 9, 2004.

42) Levin FR. Substance Abuse and ADHD. Grand Rounds at Harlem Hospital, Nov 9th, 2005, NYC.

43) Levin FR. Adolescent Substance Use: How common is it and what are parents to do?, March 13th, 2006. Teaneck High School Parent-Teacher Organization, NJ.

44) Levin FR. Substance Abuse and ADHD. Grand Rounds at The University of Texas, Houston, TX, April 5, 2006.

45) Levin FR. Marijuana Dependence: How common is it and how do we treat it? National Football League: Meeting of the Health Care Personnel, Phoenix, November 16th, 2007.

46) Levin FR. Assessment and Treatment of Adult ADHD in Substance-Abusing Patients. Grand Rounds at University of Connecticut, February 15th, 2008.

47) Levin FR. ADHD and Substance Abuse: Focus on Stimulants, Major League Baseball League: Meeting with Consulting Clinicians, Ft. Lauderdale, March 15th, 2008.

48) Levin FR. Diagnosis of ADHD: Use of the CAADID, Major League Baseball League: Meeting with Consulting Clinicians, New York, April 8th, 2008.

49) Levin FR. Evaluation and Treatment of Dual Diagnosis Disorders. Grand Rounds at University of Pennsylvania/VA, October 21st, 2008.

50) Levin FR. Targeted Treatments for Cannabis Dependence: Why is it still such a novel idea? Talk for: Intervention for Substance Abuse: Modern Research and Its Practical Applications, CME/Columbia University College of Physicians and Surgeons and New York Presbyterian, January 31, 2009, New York, NY.

51) Levin FR. ADHD, Substance Abuse and Depression: A complex clinical conundrum, Hope for Depression Research Foundation, New York, NY, November 16, 2009.

52) Levin FR. Treatment of Co-occurring ADHD and Substance Use Disorders: Implications of New Findings for Clinical Practice. Seminar at University of Minnesota, Minneapolis, MN, October 19, 2010.

53) Levin FR. ADHD and Substance Use Disorders: Diagnostic and Treatment Considerations. Grand Rounds at University of Minnesota, Minneapolis, MN, October 20, 2010.

54) Levin FR. Using the CAADID for ADHD Assessment, Major League Baseball League: Meeting with Consulting Clinicians, Washington, DC, November 7, 2010. 17

55) Levin FR. Using the CAADID for ADHD Assessment, National Football League, New York, NY November 16, 2010.

56) Levin FR. Treatment of cannabis dependence: What’s been done and where are we heading. Seminar at University of Pennsylvania, November 22, 2010

57) Levin FR. Conundrums of ADHD and Substance Use Disorders. Keynote Speaker at the 6th Annual Conference of The Addiction Institute of New York, March 4, 2011.

58) Levin FR. Grand Rounds Discussant: Psychiatrists’ relationships with Industry: A Principal-Agent Problem. Columbia University, New York State Psychiatry Institute, November 30, 2012

59) Levin FR. Assistance for Impaired Medical Students (AIMS) Addiction Rounds. The Impaired Health Professional. Columbia University, April 2, 2013

60) Levin FR, Evans EA. Psychiatric Comorbidities: Diagnosis and Treatment of Comorbid Psychiatric Disorders and Opioid Use Disorders, AAAP, PCSS-MAT Online Module, July 24, 2014.

61) Levin FR. ADHD and Substance Use Disorders in Youths and Adults. American Academy of Addiction Psychiatry 25th Annual Meeting, Aventura, FL, December 3, 2014.

62) Levin FR. Treatment of Cannabis Dependence. American Academy of Addiction Psychiatry 25th Annual Meeting, Aventura, FL, December 6, 2014.

63) Levin FR. Cannabinoids and Cannabis Use Disorder: New Directions. Annual Psychopharmacology Update: Nevada Psychological Association, Las Vegas, NV, February 13, 2015.

64) Levin FR. Psychotherapeutic and Pharmacological Intervention for Substance Use Disorders. Major League Baseball League: Meeting with Consulting Clinicians, New York, July 24, 2015.

65) Levin FR. Treating ADHD in Patients with Substance Use Disorders. National Center on Addiction and Substance Abuse-Columbia (CASAColumbia), New York, August 6, 2015.

66) Levin FR. Strategic Alliance for Medications Development to Treatment Substance Use Disorder (R01): Focus on ADHD and Substance Use Disorders. Shire, New York, September 3, 2015.

67) Levin FR. ADHD and Substance Use Disorders in Youths and Adults in Addiction Psychiatry Review Course. American Academy of Addiction Psychiatry 26th Annual Meeting, Huntington, CA, December 3rd, 2015.

SCIENTIFIC CONFERENCE PRESENTATIONS:

1) Herning R, Glover B, Koeppl B, Reddish R, Levin FR, Dax E: Cognitive deficits during cocaine abstinence persists. Committee on Problems of Drug Dependence 1990: 52nd 18

Annual Meeting, Richmond, VA.

2) Diagnostic and treatment issues in dual diagnosis: Attention deficit hyperactivity disorder and substance abuse. American Psychiatric Association Annual Meeting, May 22, 1994.

3) Issues in substance abuse. Workshop discussant. American Psychiatric Association Annual Meeting, Philadelphia, PA, May 26, 1994.

4) Physicians in residence program: A novel substance abuse training approach for residents in primary care specialties. Association for Medical Education and Research in Substance Abuse, Bethesda, MD, November 19, 1994.

5) Fischman MW, Foltin RW, Levin FR, Christiansen I. Cocaine use by opiate dependent humans: effects of buprenorphine or methadone maintenance. College on Problems of Drug Dependence 1994: 56th Annual Meeting, West Palm Beach.

6) Levin FR, Evans SM, Lugo L, Seham JC, Baird D, Kleber HD. ADHD in cocaine abusers: Psychiatric Comorbidity and pattern of drug use. College on Problems of Drug Dependence 1996: 58th Annual Meeting, Puerto Rico.

7) Levin FR. Comorbidity Conundrums: Issues in Diagnosing and Treating Cocaine Abusers with Adult ADHD. Workshop at American Psychiatric Association Annual Meeting, San Diego, CA, May 21, 1997.

8) Levin F, Evans SM, Rosenthal M, and Kleber HD: Psychiatric comorbidity in cocaine abusers in outpatient settings or a therapeutic community: Oral Communications: Psychiatric Comorbidity in Drug Abusers. College on Problems of Drug Dependence 1997: Annual Meeting, Nashville TN.

9) Levin F: Treatment of substance abuse and adult ADHD. American Academy of Addiction Psychiatry: 8th Annual Meeting, San Antonio, TX, December 7th, 1997.

10) Levin F: Conundrums of Comorbidity. Symposium Chair. American Psychiatric Association 151st Annual Meeting, Toronto, CN, June 2nd, 1998.

11) Levin F, McDowell, D, Evans, S, Kleber, HD, Brooks DA. Diagnosis and treatment of substance abusers with ADHD. American Psychiatric Association 151st Annual Meeting, Toronto, CN, June 2nd, 1998.

12) Levin F. Recent Advances in Medicine: The Effects of Perinatal Exposure to Cocaine. Symposium Chair. Brief Remarks and Overview. American Psychiatric Association 151st Annual Meeting, Toronto, CN, June 2nd, 1998.

13) Levin F. Psychotherapy with a Substance-Abusing Patient. Clinical Case Conference. American Psychiatric Association 151st Annual Meeting, Toronto, CN, June 1st, 1998. Conundrums of Comorbidity.

14) Levin F. Pharmacologic treatment of cocaine abusers with adult ADHD. Symposium on “Agonist-type approaches to the treatment of cocaine dependence, John Roache and John Grabowski, chairs. College on Problems of Drug Dependence 1998: 60th Annual Meeting, Scottsdale, AZ.

15) Sullivan MA, Levin FR, Coomaraswamy S, Fischman MW. Patterns of nicotine use among outpatients with schizophrenia or schizoaffective disorder. Oral Communications. College on Problems of Drug Dependence 1998: 60th Annual Meeting

16) Levin FR. Adult ADHD in Substance Abusers: Diagnostic and Treatment. Round Table Expert, American Academy of Addiction Psychiatry: 9th Annual Meeting, Amelia Island, FL, December 5th 1998

17) Methamphetamine: Clinical and Scientific Update. Symposium Chair at the American Academy of Addiction Psychiatry, Amelia Island, FL, December 5th, 1998.

18) Levin F. Pharmacologic treatment of cocaine abusers with adult ADHD. Symposium on “Agonist-type approaches to the treatment of cocaine dependence, John Roache and John Grabowski, chairs. College on Problems of Drug Dependence 1998: 60th Annual Meeting, Scottsdale, AZ.

19) Levin F, McDowell, D, Evans, S, Kleber, HD, Brooks DA. Diagnosis and treatment: Substance Abusers with ADHD. American Psychiatric Association 152nd Annual Meeting, Washington, D.C. May 19th, 1998.

20) Levin F: Substance Abuse and Psychiatric Comorbidity. American Psychiatric Association 152nd Annual Meeting, Washington, D.C., May 18th, 1999.

21) Levin F. Modern Management of Menopause. Chair. Brief Remarks and Overview. American Psychiatric Association 152nd Annual Meeting, Washington, D.C., May 17th, 1999.

22) Levin F. Biobehavioral Treatment of Addictive Disorders. Workshop. American Psychiatric Association 152nd Annual Meeting, Washington, D.C. May 19th, 1999.

23) Levin FR, Evans SM, Abi-Dargham A, Kegeles L. Sia A, Zea-Ponce Y, Laruelle M. SPECT Imaging of amphetamine-induced dopamine release in cocaine abusers with adult ADHD compared to controls. College on Problems of Drug Dependence 61st Annual Meeting, Acapulco, MX, June 15, 1999.

24) Akerele E, Levin FR, Nunes E, Brady R, Pierce D, Kleber HD. The effects of triple therapy and gender on methadone levels in methadone maintained patients. College on Problems of Drug Dependence 61st Annual Meeting, Acapulco MX, June 14, 1999.

25) Levin FR. Schizophrenia and Stimulant Abuse. FASEB Summer Conference on “Biological Vulnerability to Alcoholism and Drug Addiction. Copper Mountain CO, August 3rd, 1999.

26) Levin F: Substance Abuse: Cutting-Edge Treatments, Co-Chair of Symposium, American Psychiatric Association 153rd Annual Meeting, Chicago May 16th, 2000.

27) Levin F. Treatment of Comorbid Conditions. American Psychiatric Association 151st Annual Meeting, 153rd Annual Meeting, Chicago, May 16th, 2000.

28) Frances RJ, Levin F, Miller S, Millman R. Addiction Psychiatrists, HMOs and Patient Relationships. Annual Workshop at the American Psychiatric Association 153rd Annual Meeting, Chicago, May 17th, 2000. 20

29) Levin FR. New Treatments for the Dually-Diagnosed Patient. In Addiction: Gambling and Substance Abuse: Cutting Edge Treatment. Symposium Chair: Herbert D. Kleber, at the American Psychiatric Association 154th Annual Meeting, New Orleans, May 7th, 2001.

30) Levin FR. Opiate Dependence and Bipolar Disorder. In: A Most Common Challenge: The Dual-Diagnosed Patient, Chair: Roger Peele, at the American Psychiatric Association 154th Annual Meeting, New Orleans, May 8th, 2001.

31) Greenberg WE, Levin FR, Strain JJ, Yudofsky SC (Participants). Does the Mind Meet the Brian in Residency? And What About the Body? Chair: Avram Mack, at the American Psychiatric Association 154th Annual Meeting, New Orleans, May 8th, 2001.

32) Blume SB, Frances RJ, Galanter M, Levin FR, Solursh LP (Participants) Biobehavioral Integration of Addiction Treatment. Chair: Richard Frances at the American Psychiatric Association 154th Annual Meeting, New Orleans, May 10th, 2001.

33) Wilson JJ, Levin FR. Workshop: Treating ADHD Among Families Suffering for Addiction, 12th Annual Meeting, American Academy of Addiction Psychiatry, Dec 14th, 2001.

34) Weiss RD, Levin FR, Nunes EV. Workshop: Developing a Research Career: In industry, academia, and the public sector, 12th Annual Meeting, American Academy of Addiction Psychiatry, Dec 14th, 2001.

35) Levin, FR. Lunch with the Experts: ADHD and Substance Abuse, 12th Annual Meeting, American Academy of Addiction Psychiatry, Dec 14th, 2001.

36) Levin FR. “Pharmacologic Treatments for Substance Abusers with Psychiatric Comorbidity: What does the treatment literature tell us?” Symposium chaired by Herbert Kleber: Addictions: Cutting Edge Treatments for Gambling and Substance Abuse. 155th Annual Meeting of the APA, Philadelphia, May 20th, 2002.

37) Levin FR. Addiction Treatment: New Directions. Panel including: Sheila Blume, Marc Galanter, Richard Frances, Sheldon Miller, Robert Millman. 155th APA Annual Meeting, Philadelphia May 21st, 2002.

38) Levin FR. Discussion Group: Treating Substance Abusers with Psychiatric Comorbidity: Common Pitfalls. 155th Annual Meeting, May 21st, Philadelphia, 2002.

39) Levin FR. “Stimulant treatment for cocaine dependence” Symposium chaired by Marc Galanter: New Development in Medications for the Treatment of Stimulant Abuse. 155th Annual Meeting of the APA, Philadelphia, May 21st, 2002.

40) Levin FR. Treatment of Comorbid Conditions. In Addictions: Cutting Edge Treatments. Symposium Chair: Herbert D. Kleber, at the American Psychiatric Association 156th Annual Meeting, San Francisco, May 20th, 2003.

41) Levin FR, Evans SM, Horton T, Brooks DJ, Ng J, Vosburg SK. Impact of ADHD and other psychopathology on treatment outcome. In oral presentations “Double Trouble.” at

College on Drug Dependence 65th Annual Meeting, Bal Harbour, Florida, June 16th, 2003.

42) Kalbag AS, Brooks DJ, Nunes EV, Evans SM, and Levin FR. The relationship between the specific and nonspecific ADHD symptoms and addiction severity in a methadonemaintenance sample of adults with ADHD. . In oral presentations “Double Trouble.” at College on Drug Dependence 65th Annual Meeting, Bal Harbour, Florida, June 16th, 2003.

43) Bisaga A, Aharonovich E, Levin F, Rubin E, Raby W, Nunes E. Gabapentin treatment of cocaine dependence. In oral presentations “Innovative interventions: novel medications” at College on Drug Dependence 65th Annual Meeting, Bal Harbour, Florida, June 16th, 2003.

44) Levin, FR. Oral Presentation Chair for “Double Trouble.” College on Drug Dependence 65th Annual Meeting, Bal Harbour, Florida, June 16th, 2003.

45) Levin FR. Symposium Chair. Wilens TE, Riggs P, Wilson JJ. Adolescent Substance Abusers with Psychiatric Co-Morbidity: What are the most clinically-relevant approaches? 14th Annual Meeting of Addiction Psychiatry, New Orleans, Dec 4th, 2003.

46) Westreich LM (Workshop Chair), Crockford D, Levin FR, Ross S, Goldfarb L, Frances R. Building a Career in Addiction Psychiatry. 14th Annual Meeting of Addiction Psychiatry, New Orleans, Dec 5th, 2003.

47) Levin FR. Lunch with the experts: Substance Use Disorders and Attention-deficit Hyperactivity Disorder. 14th Annual Meeting of Addiction Psychiatry, New Orleans, Dec 5th, 2003.

48) Levin FR. Comorbidity in Marijuana-Dependent Individuals. NIDA-sponsored conference on Medications Development for Cannabis Dependence. Rockville, MD, April 19th and 20th, 2004.

49) Levin FR. “Treatment of ADHD in Stimulant-Dependent Individuals” Symposium chaired by Frank Vocci, Ph.D. : Emerging pharmacotherapies for treatment of stimulant dependence. 157th Annual Meeting of the APA, New York City, May 4th , 2004.

50) Levin FR. Symposium Chair. Turgay A, Newcorn JH, Jasinsky DR. ADHD 157th Annual Meeting of the APA, New York City, May 4th, 2004.

51) Levin FR. Treatment of Comorbid Conditions. In: Choosing the best treatment for substance abuse. Symposium Chair: Herbert D. Kleber, at the American Psychiatric Association 157th Annual Meeting, New York City, May 5th, 2004.

52) Levin, FR. Lunch with the Experts: Treatment of ADHD and Substance Abuse, 15th Annual Meeting, American Academy of Addiction Psychiatry, Dec 13th, 2004.

53) Levin FR. Treatment of Adolescents with Marijuana Abuse. In: Cannabis Dependence Treatment: Where we are, Where we are going. Symposium Chair: Frank Vocci, at the American Psychiatry Association 158th Annual Meeting, Atlanta, May 24th, 2005.

54) Levin FR. Choosing the best treatments for dually-diagnosed patients. In: Choosing the best treatment for substance abuse. Symposium Chair: Herbert D. Kleber, at the American Psychiatric Association 158th Annual Meeting, Atlanta, May 25th, 2005.

55) Levin FR. Choosing the best treatments for dually-diagnosed patients. In: Choosing the best treatment for substance abuse. Symposium Chair: Herbert D. Kleber, at the American Psychiatric Association 159th Annual Meeting, Toronto, Canada, May 23th, 2006.

56) Levin Fr. Substance Abuse and ADHD. New Clinical Drug Evaluation Unit (NCDEU) 46th Annual Meeting, June 14, 2006.

57) Levin FR. Evaluation and Treatment of ADHD and Substance Abuse. ISAM Scientific Conference, Oporto, Portugal, September 28, 2006.

58) Levin FR, Mariani J. Stimulant pharmacotherapy in patients with substance use disorders: can it be done safely? Abstract for American Academy of Addiction Pscyhiatry, 17th Annual Meeting and Symposium, St Pete Beach, FL, December 7-10, 2006.

59) Levin FR. Treatment issues with substance-abusing adults with ADHD. Lunch with the experts. Abstract for American Academy of Addiction Psychiatry, 17th Annual Meeting and Symposium, St Pete Beach, FL, December 7-10, 2006.

60) Levin FR. Treatment of Substance Abusers with Psychiatric Comorbidity. In: Choosing the best treatment for substance abuse. Symposium Chair: Herbert D. Kleber, at the American Psychiatric Association 160th Annual Meeting, San Diego, California, May 22, 2007.

61) Levin FR. Treatment of Comorbid ADHD and Substance Abuse Disorder. 115th Convention American Psychological Association Convention, San Francisco, CA, August 18, 2007.

62) Levin FR. Substance Abuse and Psychiatric Comorbidity. 4th Annual International Jellinek Mentrum Conference, Amsterdam, November 8th, 2007.

63) Levin FR. Treating ADHD in Substance Abusers: Can it be done safely? 4th Annual International Jellinek Mentrum Conference, Amsterdam, November 8th, 2007.

64) Levin FR. Diagnosing and Treating ADHD in Substance Abusers. 4th Meeting of the International Collaboration on ADHD and Substance Abuse (ICASA). Amsterdam, November 9th, 2007.

65) Levin FR (Co-Chair). Symposium I: Methamphetamine. American Academy of Addiction Psychiatry 18th Annual Meeting, Coronado, California, November 29, 2007.

66) Levin FR. Lunch with the Experts. Treating ADHD and Substance Abuse. American Academy of Addiction Psychiatry 18th Annual Meeting, Coronado, California, November 30, 2007.

67) Levin FR. Choosing the Right Treatment for Cannabis Dependence. In: Choosing the Right Treatment for Substance Abuse, Symposium Chair: Herbert Kleber at the 23

American Psychiatric Association 161st Annual Meeting, Washington D.C. May 6th, 2008.

68) Levin FR. Investigator’s strategies to cope with clinical trial requirements. In: Clinical Trials of Drug Abuse Pharmacotherapies: Tools and strategies to ensure compliance with current regulations., Workshop Chairs: Robert L. Wash and Ivan D. Montoya at the College on Problems of Drug Dependence 70th Annual Meeting, Puerto Rico, June 17th, 2008.

69) Levin FR. Medications to treat adults with comorbid ADHD and Substance Use Disorders. In: Advances in the Development of Medications for Comorbid ADHD and Substance Use Disorders. Symposium Chairs: Petra Jacobs and Frances R. Levin. College on Problems of Drug Dependence 70th Annual Meeting, June 18th, 2008.

70) Levin FR. Writing Grants: Advise to K Awardees. NIDA Meeting for K Awardees. Bethesda, MD, July 24th, 2008.

71) Levin FR. Medication to Treat Adults with Comorbid ADHD and Substance Use Disorder. 1st International Barcelona Meeting of ADHD & Substance Abuse, Barcelona, Spain, September 18, 2008.

72) Levin FR. Treatment of Adolescents with Comorbid Marijuana Dependence and Other Psychiatric Disorders. American Academy of Child & Adolescent Psychiatry, Chicago, IL, October 30, 2008.

73) Levin FR (Chair). Symposium II: Treatment of Substance Abuse: European Experiences American Academy of Addiction Psychiatry 19th Annual Meeting, Boca Raton, Florida December 5th, 2008.

74) Levin FR. Lunch with the Experts. Treatment of Cannabis Dependence. American Academy of Addiction Psychiatry 19th Annual Meeting, Boca Raton, Florida, December 6th, 2008.

75) Levin FR. 2008-2009 Psychiatry Grand Rounds Series at the Medical University of South Carolina. Assessment and Treatment of Adult ADHD in Substance Abusing Patients. South Carolina, February 20, 2009

76) Levin FR. Assessment and Treatment of ADHD and Substance Abuse. 6th Meeting of the International Collaboration on ADHD and Substance Abuse (ICASA). Stockholm, March 25, 2009.

77) Levin FR. Diagnosis Challenges for Co-occurring ADHD and Substance Use Disorders In: Spotting the Wolf in Sheep’s Clothing: Clinical Challenges Identify and Treating Upresented Comorbidity, Symposium Chair: Wilson M. Compton at the American Psychiatric Association 162nd Annual Meeting, San Francisco, May 18, 2009.

78) Levin FR. Choosing Treatment for Cannabis Dependence. In: Choosing the Right Treatment for Substance Abuse, Symposium Chairs: Herbert Kleber and Frances R. Levin at the American Psychiatric Association 162nd Annual Meeting, San Francisco, May 20, 2009.

79) Levin FR. Marijuana. Share the Vision Lunch. American Academy of Addiction Psychiatry, 20th Annual Meeting and Symposium, Los Angeles CA, December 5th, 2009.

80) Levin FR. Evaluation and Treatment of ADHD: Clinical Implications of New Research Findings. In: Treatment of Co-Occurring Substance Use and Attention Deficit Hyperactivity Disorder: New Findings From the NIDA Clinical Trials Network, Symposium Chair: Edward Nunes at the American Academy of Addiction Psychiatry 20th Annual Meeting and Symposium, Los Angeles CA, December 5th, 2009.

81) Levin FR. Dronabinol for cannabis addiction treatment. In: Update on Medications Development: Promising New Treatments for Drug Addictions – Chair: David J. McCann, PhD at the American Psychiatric Association 163rd Annual Meeting, New Orleans, LA, May 24, 2010.

82) Levin FR. Choosing treatments for cannabis dependence: What are the options? In: Choosing the Right Treatment for Substance Abuse, Symposium Chairs: Herbert Kleber and Frances R. Levin at the American Psychiatric Association 163rd Annual Meeting, New Orleans, LA, May 24, 2010.

83) Levin FR. Dronabinol for the treatment for cannabis dependence. In: Medications development for the treatment of substance dependence: Status of advance projects – Chair: David J. McCann, PhD at the College on Problems of Drug Dependence 72nd Annual Meeting, Scottsdale, AZ, June 15th, 2010.

84) Levin FR. Discussant: Gender Differences in ADHD, Substance Use, and Other Comorbid Psychiatric Disorders: Implications for Treatment of Adolescent and Young Adult Females. American Academy of Child & Adolescent Psychiatry 57th Annual Meeting, New York, NY, October 29, 2010.

85) Levin FR. Treatment of ADHD in Substance Abusers. American Professional Society of ADHD and Related Disorders (APSARD), Washington, DC, November 5-6, 2010.

86) Levin FR and Mariani JJ. Workshop: New Developments in Treating Marijuana Use Disorders. 21st Annual Meeting, American Academy of Addiction Psychiatry, Boca Raton, FL, Dec 3, 2010.

87) Levin, FR. Lunch with the Experts: ADHD and Substance Abuse, 21st Annual Meeting, American Academy of Addiction Psychiatry, Boca Raton, FL, Dec 4, 2010.

88) Levin FR. Choosing treatments for cannabis dependence. In: Choosing the Right Treatment for Substance Abuse, Symposium Chair: Herbert Kleber at the American Psychiatric Association 164th Annual Meeting, Honolulu, HI, May 14, 2011.

89) Levin F. Attention Spectrum Disorders. Chair Symposium, American Psychiatric Association 164th Annual Meeting, Honolulu, HI, May 18, 2011.

90) Levin FR. Psychiatric Disorders and Comorbid Substance Abuse: Prevalence and Treatment Correlates. 5th ALBATROS – International Congress of Addictology, Paris, France, June 10, 2011.

91) Levin FR. How to write a grant application: The next step toward an independent research career. NIDA Grant Writing Workshop at the College on Problems of Drug Dependence 73rd Annual Scientific Meeting, Hollywood, FL, June 21, 2011.

92) Levin FR. Lunch with the Experts: New developments in treatment ADHD and Substance Abuse, 22nd Annual Meeting, American Academy of Addiction Psychiatry, Scottsdale, AZ, December 10th, 2011.

93) Levin FR. Medications to treat cannabis dependency. In: Advances in Addiction Psychopharmacology Symposium Chair: Henry R. Kranzler at the American Psychiatric Association 165th Annual Meeting, Philadelphia, PA, May 6, 2012.

94) Levin FR. Innovative substance abuse research findings: What are the barriers to implementation? Symposium Chair, American Psychiatric Association 165th Annual Meeting, Philadelphia, PA, May 7, 2012.

95) Levin FR. Choosing treatments for cannabis dependence. In: Choosing the treatment for cannabis dependence, Symposium Chair: Herbert Kleber at the American Psychiatric Association 1165th Annual Meeting, Philadelphia, PA, May 8, 2012.

96) Levin FR. Treatment issues for co-occurring ADHD and SUD. 9th Meeting of the International Collaboration on ADHD and Substance Abuse (ICASA).Bordeaux, France, September 13, 2012.

97) Levin, FR. ADHD and Substance Use Disorders in Youth and Adults, American Academy of Addiction Psychiatry 23rd Annual Meeting, Aventura, FL, December 7, 2012.

98) Levin FR. Treatment of ADHD and SUDs: Review. III International Congress Dual Pathology, Barcelona Spain, October 23-26, 2013.

99) Levin, FR. ADHD and Substance Use Disorders in Youth and Adults, Addiction Review Course; American Academy of Addiction Psychiatry 24th Annual Meeting, Scottsdale, AZ, December 4, 2013.

100) Levin FR. “Pharmacologic treatments for cannabis use disorders: What do we know” Symposium chaired by Kevin P. Hill, MD: Marijuana: What Clinicians Need to Know. American Academy of Addiction Psychiatry 24th Annual Meeting, Scottsdale, AZ, December 5, 2013.

101) Levin FR. Pharmacologic Treatment of Attention-Deficit Hyperactivity Disorder in those with Substance Use Disorders, Presidential Symposium Chairs: Steven L. Batki, MD & Jeffrey Devido, MD at the American Psychiatric Association 167th Annual Meeting, New York, NY, May 4, 2014.

102) Levin FR. Choosing Treatment for Cannabis Use Disorders. In: Choosing the treatment for cannabis dependence, Chairs: Herbert D. Kleber, MD & Edward Nunes, MD at the American Psychiatric Association 167th Annual Meeting, New York, NY, May 6, 2014.

103) Levin FR. Medication Treatment for Cannabis Use Disorders. In: Advances in Addiction Psychopharmacology, Chairs: Domenic A. Ciraulo, MD and John A. Renner,

Jr., MD at the American Psychiatric Association 167th Annual Meeting, New York, NY, May 7, 2014.

104) Levin FR. Mixed amphetamine salts-extended release for ADHD adults with cocaine use disorder. In: Focusing Attention on ADHD and Addiction, Chairs: Frances R. Levin, MD and Sonam O. Lasopa, MD at the College on Problem of Drug Dependence 76th Annual Scientific Meeting, San Juan, PR, June19, 2014.

105) Levin FR. Extended Release Mixed Amphetamine Salts and Topiramate for Cocaine Dependence: A Randomized, Double-Blind, Placebo-Controlled Trial. 17th World Congress of Basic and Clinical Pharmacology, Cape Town, South Africa, July 17, 2014.

106) Levin FR. Choosing Best Treatment for Cannabis Use Disorder: What are the options? American Psychiatric Association 66th Institute on Psychiatric Services, San Francisco, CA, November 2, 2014.

107) Levin FR. Emerging Problems in Addiction Workshop, Chair: Frances R. Levin, MD, Presenters: Timothy Fong, MD and Mark Klieman, MD. American Psychiatric Association 66th Institute on Psychiatric Services, San Francisco, CA, November 2, 2014.

108) Mariani JJ, Levin FR, Bisaga A. Psychostimulant Treatment of Cocaine and Other Stimulant Use Disorders: It is Time Yet? American Academy of Addiction Psychiatry 25th Annual Meeting, Aventura, FL, December 4, 2014.

109) Fireman M, Saxon A, Edgar L, Levin FR, Kampman K. The Addiction Psychiatry Milestones – Questions and Answer. American Academy of Addiction Psychiatry 25th Annual Meeting, Aventura, FL, December 5, 2014.

110) Levin FR. Maintenance of Certificate Workshop (MOC). American Academy of Addiction Psychiatry 25th Annual Meeting, Aventura, FL, December 5, 2014.

111) Levin FR. ADHD as a Casual Factor in Dual Disorders. IV International Congress Dual Pathology, Barcelona Spain, April 17-20, 2015.

112) Levin FR. Diagnosing ADHD in Patients with Substance Use Disorders. IV International Congress Dual Pathology, Barcelona Spain, April 17-20, 2015.

113) Levin FR. Medication Treatment for ADHD and Substance Use Disorder. IV International Congress Dual Pathology, Barcelona Spain, April 17-20, 2015.

114) Levin FR. Treatment for ADHD and Cocaine Use Disorder. IV International Congress Dual Pathology, Barcelona Spain, April 17-20, 2015.

115) Levin FR. Choosing Treatment for Cannabis Use Disorders. In: Choosing the treatment for cannabis dependence, Chairs: Herbert D. Kleber, MD & Edward Nunes, MD at the American Psychiatric Association 168th Annual Meeting, Toronto, Canada, May 16-20, 2015

116) Levin FR. Diagnosing Treating Cannabis Use Disorders. In: Marijuana in 2015: State of the Policy and Treatment, Chairs: Laurence Westreich, MD and Kevin Hill, MD at the

American Psychiatric Association 168th Annual Meeting, Toronto, Canada, May 16-20, 2015. 116)

117) Levin FR. Treatment Strategies for Cannabis Use Disorder. In: Buprenorphine in the Treatment of Addiction: Past, Present, Future, Chairs: Marc Galanter, MD and Herbert Kleber, MD at the American Psychiatric Association 168th Annual Meeting, Toronto, Canada, May 16-20, 2015.

118) Levin FR. ADHD and Substance Use Disorder: Treatment Options. 9th Albatros Congress Addictology, Paris, France, June 12, 2015.

119) Levin FR. Medication Treatment for ADHD and Substance Use Disorder. ICASA Conference, Stockholm, Sweden, June 15, 2015.

120) LaBelle C, Horey J, Nunes E. Approaches to Implementing Medication Assisted Treatments of Opioid Use Disorder in the Community and the Role of PCSS-MAT Program. Chair: Frances R. Levin. American Academy of Addiction Psychiatry 26th Annual Meeting, Huntington Beach, CA, December 4, 2015.

121) Krahn D, Ford JH, Giles M, Oliver KA. New Development in Maintenance of Certification (MOC) Performance Improvement Skills including AAAP Social Media Supports to Improve your Practice. Chair: Frances R. Levin. American Academy of Addiction Psychiatry 26th Annual Meeting, Huntington Beach, CA, December 5, 2015.

122) Levin FR. Lunch with the Experts: New developments in treatment ADHD and Substance Abuse, 22nd Annual Meeting, American Academy of Addiction Psychiatry, 26th Annual Meeting, Huntington Beach, CA, December 5th, 2015.

PUBLICATIONS:

1) Raslear TG, Pierrel-Sorrentino R, and Rudnick FF: Loudness scaling and masking in rats. Behavioral Neuroscience 97(3): 392-8, 1983.

2) Levin FR and Lehman A: Meta-analysis of desipramine as an adjunct in the treatment of cocaine addiction. J Clinical Psychopharmacology 11(6): 374-378, 1991.

3) Levin FR, Levin HR, and Nagoshi C: Autonomic functioning and cigarette smoking: heart rate spectral analysis. Biological Psychiatry 31: 639-643, 1992.

4) Levin FR, Hess JM, Gorelick DA, Kreiter NA, and Fudala PJ: Pattern of cocaine use among cocaine-dependent outpatients. American Journal on Addictions 2(2): 109-115, 1993.

5) Hien DA and Levin FR: Trauma and trauma-related disorders for women on methadone: prevalence and treatment considerations. Journal of Psychoactive Drugs 26(4): 421-429, 1994.

6) Levin FR and Kleber HD: Attention deficit hyperactivity disorder and substance abuse: relationships and implications for treatment. Harvard Rev Psychiatry 2(5):246-258, 1995.

7) Foltin RW, Fischman MW, Levin, FR: Cardiovascular effects of cocaine in humans: laboratory studies. Drug and Alcohol Dependence 37(3): 193-210, 1995.

8) Montoya ID, Levin FR, Fudala PJ, Gorelick DA: A double-blind comparison of carbamazepine and placebo for treatment of cocaine dependence. Drug and Alcohol Dependence).38: 213-219, 1995.

9) Evans SM, Foltin RW, Levin FR, Fischman MW: Behavioral and subjective effects of DN-2327 (Pazinaclone) and alprazolam in normal volunteers. Behavioral Pharmacology 6:176-186, 1995.

10) Foltin RW, Christiansen C, Levin FR, Fischman MW: Effects of single and multiple intravenous cocaine injections in humans maintained on methadone. Journal Pharm Exp Therap 275:38-47, 1995.

11) Levin FR, Owen P, Rabinowitz E, Pace N: Physicians in residence program: an evaluation of a novel substance abuse training program for residents in primary care specialties. Substance Abuse 17: 5-18, 1996.

12) Evans SM, Haney MJ, Levin FR, Foltin RW, Fischman MW: Menstrual cycle effects in women with premenstrual syndrome. Journal European College of Neuropharmacology, 6 (suppl 3): 57, 1996.

13) Levin FR, Foltin RW, Fischman MW: Pattern of cocaine use in methadone-maintained individuals applying for research studies. Journal of Addictive Diseases 15:97-106, 1996.

14) Levin FR, Fischman MW, Connerney I, Foltin RW: A Protocol to Switch High-Dose Methadone Subjects to Buprenorphine. American Journal on Addictions 6:105-116, 1997.

15) Evans SM, Levin FR. Effects of alprazolam in women: Differences as a function of a paternal history of alcoholism. J Women’s Health 6:380, 1997.

16) Levin FR, Evan SM, Coomaraswammy S, Collins ED, Regent N, Kleber HD Flupenthixol treatment for cocaine abusers with schizophrenia: a pilot study. American Journal of Drug and Alcohol Abuse 24:343-360, 1998.

17) Levin FR, Evans SM, McDowell D, Kleber HD: Methylphenidate treatment for cocaine abusers with adult attention-deficit/hyperactivity disorder: a pilot study. Journal of Clinical Psychiatry, 59:300-305, 1998.

18) Levin FR, Evans SM, Kleber HD: Prevalence of adult attention-deficit hyperactivity disorder among cocaine abusers seeking treatment. Drug and Alcohol Dependence 52:15-25, 1998.

19) Evans SM, Haney M, Levin FR, Foltin RW, Fischman MW: Mood and performance changes in women with premenstrual syndrome: effects of alprazolam. Neuropsychopharmacology 499-516, 1998.

20) Evans SM, Levin FR, Fischman MW, Foltin RW. Smoked cocaine self-administrationin females and voucher incentives for abstinence. Journal of Substance Abuse 10:143-162, 1998. 29

21) Levin FR, Owen P, Stinchfield R, Rabinowitz E, Pace N: Use of standardized patients to evaluate the Physicians in Residence Program: A Substance Abuse Training Approach. Journal of Addictive Diseases 18: 39-50, 1998.

22) Muskin PR, Stevenson EM, Levin FR: A multiple diagnosis approach to behavioral symptoms in medically ill patients. Journal Practical Psychiatry and Behavioral Health 4:356-362, 1998.

23) McDowell DM, Levin FR, and Nunes EV: Dissociative Identity Disorder and Substance Abuse: The Forgotten Relationship. Journal of Psychoactive Drugs 31:71-83, 1999.

24) Levin FR, Owen P, Stinchfield R, Rabinowitz E, Pace N: Use of standardized patients to evaluate the Physicians in Residence Program: A Substance Abuse Training Approach. Journal of Addictive Diseases, 1999; 18:39-50.

25) Levin FR, McDowell D, Evans SM, Brooks D, Spano C, Nunes EV: Pergolide Mesylate for cocaine abuse: a controlled preliminary trial. American Journal on Addictions 8:120- 127, 1999.

26) Levin FR, Evans SM, Kleber HD: Treatment of Substance Abusers with Adult ADHD: Practical guidelines for Treatment. Psychiatric Services 50: 1001-1003, 1999.

27) Levin FR, Donaldson PL: Diagnosis and Treatment of Adult Substance Abusers with ADHD Directions in Psychiatry 19(3); 251-266, 1999.

28) Hien DA, Nunes EV, Levin FR: PTSD and short-term outcome in early methadone Treatment. Journal on Substance Abuse Treatment 19: 31-37, 2000.

29) McDowell D, Levin FR, Seracini A, Kleber HD: Venlafaxine for cocaine abusers with depression. American Journal Drug and Alcohol Abuse. 26: 25-31, 2000.

30) Evans SM, Levin FR, Fischman MW: Increased sensitivity to alprazolam in females with a paternal history of alcoholism. Psychopharmacology 150: 150-162, 2000.

31) Levin FR, Bisaga A, Kleber H. Pharmacologic treatments for substance abuse: Current and Promising. Trends in Evidence Based neuropsychiatry, 2:10, 32-40, 2000.

32) Levin FR, Bisaga A, Kleber HD. Pharmacologic treatments for substance abuse. The economics of neuroscience. 2:32-40, 2000.

33) Levin FR: Substance Abuse and Adult ADHD. Psychiatric Times Feb 17:60-63, 2000.

34) Evans SM, Walsh SL, Levin FR, Foltin RW, Fischman MW, Bigelow GE. Effect of flupenthixol on the subjective and cardiovascular effects of intravenous cocaine in humans. Drug and Alcohol Depend. 64:271-283, 2001.

35) Aviram RB, Rhum M, Levin FR. Psychotherapy of adults with comorbid attention deficit hyperactivity disorder and psychoactive substance use disorder. J Psychother Pract Res 10:179-186, 2001.

36) Levin FR, Evans SM. Dual Diagnosis: Where we are and where we are heading. 30

Psychiatric Annals 31: 241-242, 2001.

37) Levin FR, Evans. Diagnostic and Treatment Issues in Comorbid Substance Abuse and Adult Attention-Deficit Hyperactivity Disorder. Psychiatric Annals 31:303-312, 2001.

38) Wilson J, Levin. Attention Deficit Hyperactivity Disorder (ADHD) and Substance Use Disorders. In: Current Psychiatric Reports: Mood Disorders and Substance Use Disorders. RO Friedel and DL Evans, eds.; RD. Weiss, Section Ed. 3: 497-506, 2001.

39) Akerele E, Levin FR, Nunes EV, Brady R, Kleber H. Effects of triple therapy on methadone levels. Am J Addictions 11: 308-314, 2002.

40) GAP Committee on Addictions: Boyarsky BK, Dilts S, Frances RJ, Frosch WA, Galanter M, Levin FR. Lewis C, Loomis E,Menninger JA, Nace EP, Suchinsky R, Tamerin J, Westermeyer J, Wolkoff D, Ziedonis, D. Responsibility and Choice in Addiction: GAP Committee on Addictions. Responsibility and choice in substance use and addiction. Psychiatric Services 53: 651-782, 2002.

41) Akerele EO, Levin FR. Substance abuse among patients with schizophrenia. J Psychiatric Practice 8: 61-130, 2002.

42) Levin FR, Evans SM, McDowell DM, Brooks DJ, Nunes E. Bupropion Treatment for Cocaine Abuse and Adult Attention-Deficit/Hyperactivity Disorder. J Addictive Diseases 21: 1-16, 2002.

43) Evans SM and Levin FR. The effects of alprazolam and buspirone in light and moderate female social drinkers. Behavioural Pharmacology 13: 427-439, 2002.

44) Agosti V, Nunes E, Levin F. Rates of psychiatric comorbidity among United States residents with lifetime cannabis dependence. Am J Drug & Alcohol Abuse 28: 643-652, 2002.

45) Evans SM, Levin FR. Response to alcohol in females with a paternal history of alcoholism. Psychopharmacology 169: 10-20, 2003.

46) Levin FR, McDowell DM, Evans SM, Nunes E, Akerele E, Donovan S, Vosburg SK. Pharmacotherapy for Marijuana Dependence: A Double-Blind, Placebo-Controlled Pilot Study of Divalproex Sodium. American Journal on Addictions. Jan-Feb 13(1): 21-32, 2004.

47) Agosti V., Levin F.R. Predictors of treatment contact among individuals with cannabis dependence. Am Journal Drug Alcohol Dep 30(1): 121-127, 2004.

48) Nunes EV, Levin FR. Treatment of depression in patients with alcohol and drug dependence: a meta-analysis. JAMA 291(15): 1887-1896, 2004.

49) Evans SM, Levin FR. Differential response to alcohol in light and moderate female social Drinkers. Behavioral Psychopharmacology 15: 167-181, 2004.

50) Levin FR, Evans SM, Vosburg SK, Horton T, Brooks D, Ng J. Impact of Attention- deficit hyperactivity disorder and other psychopathology on treatment retention in a therapeutic community 29: 1875-1882, 2004. 31

51) Levin FR, Hennessy G. Bipolar Disorder and Illicit Drugs. Biol Psychiatry 15:738-48, 2004.

52) O’Brien CP, Charney DS, Lewis L, Cornish JW, Litten RZ, Post RM, Woody GE, Zubieta J, Andreason PJ, Anthony JC, Battle W, Blaine JD, Bowden CL, Calabrese JR, Carroll K, Childress AE, Compton WM, Davis MA, Demartino R, Drake RE, Fleming MF, Fricks L, Glassman AH, Insel TR, Johnson RL, Jordan C, Kessler RC, Kosten T, Laden SK, Le Fauve CE, Levin FR, Li TK, McLellan T, Nunes EV, Oslin DW, Pettinati H, Regier DA, Renner JA, Ries RK, Rounsaville, Sklar-Blake T, Tai B, Volkow ND, Weisner C. Priority actions to improve the care of persons with co-occurring substance abuse and other mental disorders: a call to action. Biol Psychiatry 15: 103-13, 2004.

53) Nunes EV, Sullivan M, and Levin FR. Treatment of depression in patients with opiate. Dependence. Biol Psychiatry 15: 193-802, 2004.

54) Mariani J, Levin FR. Pharmacotherapy for alcohol-related disorders: what clinicians should know. Harvard Review of Psychiatry 12(6): 351-366, 2004.

55) Bisaga A, Aharonovich E, Levin FR, Rubin E, Raby W, Garawi F, Vosburg S, Nunes EV. Utility of placebo lead-in period in cocaine treatment pharmacotherapy trials. Drug Alcohol Depend 1:7-11, 2005.

56) Gunderson EW, Levin Frances R, Smith L. Screening and intervention for alcohol and illicit drug use: A survey of internal medicine housestaff. J Addictive Diseases 24: 1-17, 2005.

57) Wilson JJ, Levin FR. ADHD and Early Onset Substance Use Disorders. T Wilens, ed. Journal Child Adolescent Psychopharmacology, Special Issue of Psychopharmacology and Substance Abuse 15: 751-763, 2005.

58) Kalbag AS, Levin FR. Adult ADHD and Substance Abuse: Diagnostic and Treatment Issues Substance use and misuse 40: 1955-81, 2005.

59) Kalbag AS, Levin FR. The most critical contemporary unresolved issues associated with the pharmacotherapy treatment of substance abuse. Subst Use Misuse 40(14): 2043-8, 2005.

60) Mariani JJ, Levin FR. Treatment of comorbid conditions of substance abuse. Directions in Psychiatry 25:129-140, 2005.

61) ADHD/SUD Roundtable Meeting: Wilens TE; Faculty Advisors: Bukstein SG, Daviss WB, Goodman DW, Grabowski J, Kollins SH, Levin FR, Renner JA, Schubiner H, Upadhyaya H, Young JL. A Closer Look at Substance Use Disorders in Individuals with ADHD. CME Monograph. Sponsored by University of Michigan Medical School, Prepared by JB Ashtin Group, Inc. 2005.

62) Collins SL, Levin FR, Foltin RW, Kleber HD, Evans SM. Response to cocaine, alone and in combination with methylphenidate, in cocaine abusers with ADHD. Drug Alcohol Depend. 82(2): 158-67, 2006.

63) Agosti V, Levin FR. The effect of alcohol and drug dependence on the course of depression. Am J Addictions 15: 71-75, 2006.

64) Bisaga A, Aharonovich E, Garawi F, Levin FR, Rubin E, Raby WN, Nunes EV. A randomized placebo controlled trial of gabapentin for cocaine dependent. Drug Alcohol Depend 81:267-74, 2006.

65) Raby WN, Carpenter K, Nunes EV, Aharonovich E, Rubin E, Bisaga A, Levin Temperament characteristics, as assessed by tridimensional personality questionnaire, moderate response to sertraline in depressed opiate-dependent methadone patients. Drug and Alcohol Dependence 81: 283-92, 2006.

66) Levin FR, Evans SM, Brooks DJ, Kalbag AS, Garawi F, Nunes EV. Treatment of methadone-maintained patients with adult ADHD: double-blind comparison of methylphenidate, bupropion, and placebo. Drug and Alcohol Dependence 81: 137-48, 2006.

67) Levin FR, Brooks DJ, Raby W, Rubin E, Aharonovich, Nunes EV. Severity of dependence and motivation for treatment: comparison of marijuana and cocaine- dependent treatment seekers. J Addict Dis. 23(1): 33-41, 2006.

68) Brooks DJ, Kalbag, Vosburg S, Evans SM, Levin FR. Assessment of cognitive functioning of methadone-maintenance patients: Impact of adult ADHD and current cocaine dependence. J Addict Dis. 25(4):15-25, 2006.

69) Agosti V, Levin FR. One-year follow-up of suicide attempters treatment for drug dependence, American Journal on Addictions 15:293-296, 2006.

70) Wilson JJ, Levin FR, Donovan S, Nunes EV. Verbal predictors of attrition during adolescent substance abuse treatment. Child Psychiatry and Human Development 36(4): 393-401, 2006.

71) Nunes EV, Levin FR. Treating Depression in Substance Abusers. Current Psychiatry Reports 8(5): 363-370, 2006.

72) Gunderson EW, Fiellin DA, Levin FR, Sullivan LE, Kleber HD. Evaluation of a Combined Online and In Person Training on the Use of Buprenorphine. Substance Abuse, 27(3): 39-45, 2006.

73) Aharonovich E, Bisaga A, Garawi F, Brooks D, Raby W, Rubin E, Nunes EV, Levin FR. Concurrent cannabis use during treatment for co-morbid ADHD and Cocaine: effects on outcome. American Journal of Drug and Alcohol Abuse, 32: 629-636, 2006.

74) SUD-ADHD Academic Council: Wilens TE, Parker SJ, Bukstein OG, Grabowski J, Kaminer Y, Kazura AN, Knight JR, Levin FR, Riggs PD, Schubiner H, Sokhkhah R, Upadhyaya HP. Substance use and ADHD Understanding the links, treating the consequences. CME Activity. Sponsored by Boston University School of Medicine, Prepared by Haymarket Medical, 2006.

75) Mariani JJ, Levin FR. Stimulant Pharmacotherapy in Attention Deficit/Hyperactivity Disorder in patients with Co-occurring Substance Use Disorder. Advances in ADHD, 1(2): 47-52, 2006. 33

76) Agosti V, Levin FR. One-year post-treatment outcome of cannabis dependent adolescents. Addictive Disorders and Their Treatment, 15(4): 363-370, 2006

77) Levin FR, Evans SM, Brooks DJ. Treatment of cocaine dependent treatment seekers with adult ADHD: Double-blind comparison of methylphenidate and placebo. Drug and Alcohol Dependence, 87: 20-29, 2007.

78) Nace EP, Birkmayer F, Sullivan MA, Galanter M, Frances RJ, Fromson J, Levin FR, Lewis C, Suchinsky RT, Tamerin JS, Wastermeyer J. Socially sanctioned Coercion Mechanisms for Addiction Treatment. American Journal on Addiction, 16: 15-23, 2007.

79) Mariani, JJ, Levin FR. Treatment Strategies for Co-Occurring ADHD and Substance Use Disorders. American Journal on Addiction, 16:(S1) 45-46, 2007.

80) Evans SM, Levin FR, Brooks DJ, Garawi F. A Pilot Double-Blind Treatment Trial of Memantine for Alcohol Dependence. Alcoholism: Clinical and Experimental Research, 31:(5), 775-782, 2007.

81) Agosti V, Levin FR. Predictors of cannabis dependence recovery among epidemiological survey respondents in the United States. Journal of Addictive Diseases (In press, American Journal of Drug and Alcohol Abuse, 33(1): 81-88, 2007.

82) Agosti V, Levin FR. Predictors of abstinence among marijuana dependent adolescents. American Journal of Drug and Alcohol Abuse, 33: 81-88, 2007.

83) Rubin E, Aharonovich E, Bisaga A, Levin FR, Raby WN, Nunes EV. Early abstinence in cocaine dependence: influence of comorbid major depression. American Journal on Addiction, 16:4, 283-290, 2008.

84) Akerele E, Levin FR. Comparison of olanzapine to risperidone in substance-abusing individuals with schizophrenia. American Journal on Addictions, 16:4, 260-268, 2007.

85) Levin FR. Diagnosing ADHD in adults with substance use disorder: DSM-IV criteria and differential diagnosis. Journal of Clinical Psychiatry, 68(7): e18, 2007.

86) Mariani JJ, Levin FR. Quetiapine Treatment of Zolpidem Dependence. American J Addictions, 16, 426, 2007.

87) Nordstrom BR, Levin FR. Treatment of cannabis use disorders: A review of the literature. American J Addictions, 16, 331-42, 2007.

88) Johnson BA, Rosenthal N, Capece JA, Weigand F, Mao L, Beyers K, McKay A, Ait- Daoud N, Anton RF, Ciraulo DA, Kranzler HR, Mann K, O’Malley SS, Swift RM, Alcoholism Advisory Board, Topiramate for Alcoholism Study Group. Topiramate for treating alcohol dependence: A multi-site randomized controlled trial. JAMA, 298(14): 1641-1651, 2007.

89) Levin FR (Clinician Interview). CME Forum ADHD Practice Guide. Adult ADHD Edition, 2007.

90) Wilens, TE, Bukstein OG, Levin FR, McGough JJ, Schubiner H. Common Problems: New Solutions? A look at ADHD, Substance use disorders and the safety and abuse liability of pharmacologic agents. CME Activity Jointly sponsored by the University of California, Irvine School of medicine and Optima Educational Solutions, Inc. Sponsored by an educational grant from Shire Pharmaceuticals, Inc. , 2007

91) Rubin E, Aharonovich E, Bisaga A, Levin FR, Raby WN, Nunes EV. Early abstinence in cocaine dependence: influence of comorbid major depression. American Journal on Addiction, 16:4, 283-290, 2008.

92) Levin FR, Bisaga A, Raby W, Aharonovich E, Rubin E, Mariani J, Brooks DJ, Garawi F, Nunes EV. Effects of major depression and attention deficit/hyperactivity disorder on the outcome of treatment for cocaine-dependence. J Substance Abuse Treatment, 34(10): 80- 89, 2008

93) Sullivan MA, Birkmayer F, Boyarsky BK, Frances RJ, Fromson J, Galanter M, Levin FR, Lewis C, Nace EP, Suchinsky RT, Tamerin JS, Tolliver B, and Westermeyer J. Uses of Coercion in Addiction Treatment: Clinical Aspects. American Journal of Addictions, 17(1): 36-47, Jan-Feb, 2008.

94) Polydorou S, Levin FR. Pharmacologic treatments of alcohol dependence. Current Psychiatry, Vol 7:25-37, 2008

95) Gunderson EW, Levin FR, Owen P. Impact of a Brief Training on Substance Abuse Screening Among Medical Residents. American Journal on Addictions; Marc-Apr: 17(2): 149-54, 2008.

96) Reed SC, Levin FR, Evans SM. Changes in mood, cognitive performance and appetite in the late luteal and follicular phases of cycle in women with and without PMDD (premenstrual dysphoric disorder). Horm Behav 54(1): 185-193, 2008.

97) Levin FR, Kleber HD. Use of Dronabinol for Marijuana Dependence: Two Case Reports and Review. American J of Addictions; March-Apr: 17(2): 161-4, 2008.

98) Acosta MC, Manubay J, Levin FR. Pediatric Obesity: Parallels with addiction and treatment recommendations. Harv Rev Psychiatry; 2008 Mar-Apr; 16(2): 80-96.

99) Johnson, B.A., Rosenthal, N., Capece, J.A., Wiegand, F., Mao, L., Beyers, K., McKay, A., Ait-Daoud, N., (and in alphabetical order) Addolorato, G., Anton, R.F., Ciraulo, D.A., Kranzler, H.R., Mann, K., O’Malley, S.S., Swift, R.M., for the Topiramate for Alcoholism Advisory Board and the Topiramate for Alcoholism Study Group. Improvement of physical health and quality of life of alcohol-dependent individuals with topiramate treatment: US multisite randomized controlled trial. Archives of Internal Medicine Jun 9th 168(11): 1188-1199, 2008.

100) Mariani JJ, Horey J, Bisaga A, Aharonovich E, Raby W, Cheng WY, Nunes EV, Levin FR. Antisocial behavioral syndromes in cocaine and cannabis dependence. Am J Drug and Alcohol Abuse 34:405-414-, 2008.

101) Nunes EV, Levin FR. Treatment of co-occurring depression and substance dependence: Using a meta-analysis to guide clinical recommendations. Psychiatric Annals 38, 730- 741, 2008. 35

102) Polydorou S, Gunderson EW, Levin FR. Training physicians to treat substance use disorders. Current Psychiatry Reports, 10:399-404, 2008.

103) Mariani JJ, Levin FR. Levetiracetam fro the Treatment of Co-Occurring Alcohol Dependence Anxiety: Case Series and Review. Am J Drug Alchol Abuse, 34, 683-91, 2008.

104) Riggs P, Levin F, Green AI, Vocci F. Comobid psychiatric and substance disorders: recent treatment research. Subst Abus, 3, 51-63, 2008.

105) Carpenter K, McDowell DM, Brooks DJ, Garawi F, Levin FR. A preliminary trial: double-blind comparison of nefazodone, bupropion-SR, and placebo in the treatment of cannabis dependence. Am J Addict 1, 53-64, 2009.

106) Dakwar E, Levin FR, Nunes EV. Meditation and Psychiatry: The emerging role of meditation in the treatment of substance use disorders. Har Rev Psychiatry, 17: 254-67, 2009.

107) Agosti V, Levin FR. Does Remission from Alcohol and Drug Use Disorder Increase the Likelihood of Smoking Cessation Among Nicotine Dependent Young Adults? Social Psychiatry Psychiatr Epidemiol, 44: 120-4, 2009.

108) Gunderson EW, Coffin P, Chang N, Polydorou S, Levin FR. The interface between substance abuse and chronic pain management in primary care: A curriculum for medical residents. Subs Abuse, 30: 253-60, 2009.

109) Levin FR, Mariani J, Brooks D, Secora A, Raby W, Nunes E, Aharonovich E, Hennessy G. Atomoxetine treatment for cocaine abuse and adult attention-deficit hyperactivity disorder (ADHD): A preliminary open trial. J Dual Disorders, 5(1); 41-56, 2009.

110) Mariani JJ, Haney M, Hart C, Vosburg S, McDowell D, Levin FR. Effects of Research Setting on Observed Depressive Symptoms in Marijuana Users. J Subst Abuse Treat., 37, 431-4, 2009.

111) Levin FR, Brooks DJ, Mariani JJ, Xie S, Murray KA. Delta-9-Tetrahydrocannabivirin may not be useful to detect marijuana use among individuals ingesting dronabinol. Drug and Alcohol Dependence, 68, 65-68, 2010.

112) Gunderson EW, Wang X, Fiellin DA, Bryan B, Levin FR. Unobserved versus observed office buprenorphine/naloxone induction: A pilot randomized clinical trial. Addict Behav, 35, 537-540, 2010.

113) Secora AM, Eddie D, Wyman BJ, Brooks DJ, Mariani JJ, Levin FR. A Comparison of Psychosocial Functioning and Cognitive Functioning Between Depressed and Non- Depressed Patients with Cannabis Dependence. J Addict Dis, 29, 325-327, 2010.

114) Reed S, Levin FR, Evans SM. The effects of progesterone pretreatment on the response to oral d-amphetamine in women. Horm Behav, 58, 533-543, 2010.

115) Bisaga A, Aharonovich E, Cheng WY, Levin FR, Mariani J, Raby WN, Nunes EV. A Placebo Controlled Trial of Memantine for Cocaine Dependence with High-Value 36

Voucher Incentives During a Pre-Randomization Lead-In Period. Drug Alcohol Depend, 111, 97-104, 2010

116) Evans SM, Levin FR. Response to alcohol in women: Role of the menstrual cycle phase and a family history of alcoholism. Drug Alcohol Depend, 114(1), 1-16, 2011.

117) Mariani JJ, Brooks DJ, Haney M, Levin FR. Quantification and Comparison of Marijuana Smoking Practices: Blunts, Joints, and Pipes. Drug Alcohol Depend, 113(2- 3), 249-251, 2011.

118) Vadhan NP, van Gorp WG, Levin FR. Specificity of verbal learning impairment and recovery in a marijuana-dependent male: the effects of sustained marijuana abstinence. Cogn Neuropsychiatry. 16(2), 158-173, 2011.

119) Mysels DJ, Vosburg SK, Benga I, Levin FR, Sullivan MA. Course of weight change during naltrexone vs. methadone maintenance for opioid-dependent patients. J Opioid Manag, 7(1):47-53, 2011.

120) Dakwar E, Mariani J, Levin FR. Mindfulness Impairments in Individuals Seeking Treatment for Substance Treatment for Substance Use Disorders. Am J Drug Alcohol Abuse. 37(3): 165-169, 2011

121) Mariani JJ, Cheng W, Bisaga A, Sullivan M, Carpenter K, Nunes EV, Levin FR. Comparison of clinical trial recruitment populations: treatment-seeking characteristics of opioid-, cocaine-, and cannabis-using participants. J Subst Abuse Treat, 40(4), 426-430, 2011.

122) Levin FR, Mariani JJ, Brooks DJ, Pavlicova M, Wendy Cheng, Nunes E. Dronabinol for the treatment of cannabis dependence: A randomized, double-blind, placebo-controlled trial. Drug Alcohol Depend. 2011, 116(1-3): 142.150, 2011.

123) Donovan S, Levin FR. The young sibling at risk design: A pilot study of adolescents with ADHD and an older sibling with substance use disorder. Am J Drug Alcohol Abuse, 37(4), 235-239, 2011

124) Dakwar E, Nunes EV, Bisaga A, Carpenter KC, Mariani JP, Sullivan MA, Raby WN, Levin FR. A comparison of independent depression and substance-induced depression in cannabis-, cocaine-, and opioid-dependent treatment seekers. Am J Addict, 20(5), 441- 446, 2011.

125) Gunderson EW, Levin FR, Rombone MM, Vosburg SK, Kleber HD. Improving Efficiency of outpatient buprenorphine induction. Am J Addict, 20(5), 397-404, 2011.

126) Agosti V, Chen Y, Levin FR. Does attention Deficit Hyperactivity Disorder increase the risk of suicide attempts? J Affect Disorder, 133(3), 5595-599, 2011.

127) Bisaga A, Sullivan MA, Cheng WY, Carpenter KM, Mariani JJ, Levin FR, Raby WN, Nunes EV. A placebo controlled trial of memantine as an adjunct to oral naltrexone for opioid dependence. Drug Alcohol Depend, 119(1-2), 23-29, 2011.

128) Kirkpatrick MG, Gunderson EW, Levin FR, Foltin RW, Hart CL. Acute and residual interactive effects of repeated administrations of oral methamphetamine and alcohol in humans. Psychopharmacology (Berl), 219(1): 191-204, 2012.

129) Kirkpatrick MG, Gunderson E, Johanson, C, Levin FR, Foltin R, Hart CL. Comparison of intranasal methamphetamine and d-amphetamine self-administration by humans. Addiction, 107(40): 784-91, 2012.

130) Horey JT, Mariani JJ, Cheng WY, Bisaga A, Sullivan M, Nunes E, Levin FR. Comparison of substance use milestones in cannabis- and cocaine-dependent patients. J Addict Dis, 31(1): 60-66, 2012.

131) Mariani JJ, Levin FR. Psychostimulant treatment of cocaine dependence. Psychiatr Clin North Am, 35(2): 425-439, 2012.

132) Levin FR. Hyperactivity/impulsivity in childhood, but not inattention, is associated with early-onset tobacco and alcohol use: Commentary on The effects of childhood ADHD symptoms on early-onset substance use: a Swedish twin study by Chang et al. Evid Based Ment Health, 15(4): 102, 2012.

133) Reed SC, Levin FR, Evans, SM. Alcohol increases impulsivity and abuse liability in heavy drinking women. Exp Clin Psychopharmacol, 20(6): 454-65, 2012.

134) Mariani JJ, Brooks D, Pavlicova M, Bisaga A, Nunes EV, Levin FR. Extended release mixed amphetamine salts and topiramate for cocaine dependence: A randomized controlled trial. Biol Psychiatry, 72(11): 950-6, 2012.

135) Dakwar E, Mahony A, Pavlicova M, Glass A, Brooks D, Mariani JJ, Grabowski J, Rudnick Levin FR. The utility of attention-deficit/hyperactivity disorder screening instruments in individuals seeking treatment for substance use disorders J Clin Psychiatry, 73(11): 1372-8, 2012.

136) Herron AJ, Mariani JJ, Pavlicova M, Parinello CM, William KL, Levin FR. Nunes EV, Sullivan MA, Raby WN, Bisaga A. Assessment of riboflavin as a tracer substance: Comparison of a qualitative to a quantitative method of riboflavin measurement. Drug Alcohol Depend, 128(1-2): 77-82, 2013.

137) Kalapatapu R, Campbell A, Aharonovich E, Hu MC, Levin FR, Nunes EV. Demographic and clinical characteristics of older versus younger adults enrolled in a clinical trial of a web-delivered psychosocial treatment for substance use disorders. J Addict Med, 7(1): 66-72, 2013.

138) Reed SC, Levin FR, Evans SM. Alcohol increases impulsivity and abuse liability in heavy drinking women. J Addict Med, 7(1): 66-72, 2013

139) Levin F, Mariani J, Brooks D, Pavlicova M, Nunes E, Agosti V, Bisaga A, Sullivan M. Carpenter K. A Randomized, Double Blind, Placebo Controlled Trial of Venlafaxine- Extended release for Co-occurring Cannabis Dependence and Depressive Disorders. Addiction, 108(6): 1084-94, 2013.

140) Van de Glind G, van den Brink W, Koeter MWJ, Carpentier PJ, Barta C, Kaye, Skuttle A, van Emerik-van Oortmerseen K, Franck J, Konstenius A, Bu ET, Moggi F, Dom G, 38

Demetrovic Z, Fatseas M, Schillinger A, Kapitany-Foveny M, Verspreet S, Seitz A, Johnson B, Faraone SV, Ramos-Quiroga A, Allsop S, Sarruthers S, Schoevers RA, IASP Research Group, Levin FR. Validity of the ASRS, a screener for adult ADHD, in a large international substance abusing sample. Drug Alcohol Depend, 132(3): 587-96, 2013.

141) Sullivan, AM, Bisaga, A, Mariani JJ, Glass A, Levin FR, Comer SD, Nunes EV. Naltrexone treatment for opioid dependence: Does its effectiveness depend on testing the blockade? Drug Alcohol Depend, 133(1): 80-5, 2013.

142) van de Glind G, Van Emmerik-van Oortmerssen K, Carpentier PJ, Levin FR, Koeter MW, Barta C, Kaye S, Skutle A, Franck J, Konstenius M, Bu ET, Moggi F, Dom G, Demetrovics Z, Fatséas M, Schillinger A, Kapitány-Fövény M, Verspreet S, Seitz A, Johnson B, Faraone SV, Ramos-Quiroga JA, Allsop S, Carruthers S, Schoevers RA; Iasp Research Group, van den Brink W. The international ADHD in Substance Use Disorders Prevalence (IASP) study: Background, methods, and study population. Int J Methods Psychiatr Res. 2013 Sep 11. doi: 10.1002/mpr.1397. [Epub ahead of print]

143) Dakwar E, Levin FR, Foltin RF, Nunes EV, Hart CL. The effects of subanesthetic ketamine infusions on motivation to quit and cue-induced craving in cocaine dependent research volunteers. Biol Psychiatry, 2013 Sep 11. pii: S0006-3223(13)00738-5. doi: 10.1016/j.biopsych.2013.08.009. [Epub ahead of print]

144) Davis GP, Surratt HL, Levin FR, Blanco C. Antiretroviral medication an emerging category of prescription drug misuse. Amer J Addict 2013, DOI: 10.1111/j.1521- 0391.2013.12107.

145) Dakwar E, Levin FR. Individual Mindfulness-Based Psychotherapy for Cannabis or Cocaine Dependence: A Pilot Feasibility Trial. Amer J Addict 22(6), 521-526, 2013.

146) Davis GP, Compton MT, Wang S, Levin FR, Blanco C. Association between cannabis use, psychosis, and schizotypal personality disorder. Findings form the National Epidemiologicl Survey on Alcohol and Related Conditions. Schizophr Res, 151(1-3): 197-202, 2013.

147) Nunes EV, Covey LS, Bridham, Hu Mei-Chen, , Levin FR, Somoza EC, Winhusen T. Treating nicotine dependence by targeting attention deficit hyperactivity disorder (ADHD) with OROS Methylphenidate: The role of baseline ADHD severity and treatment response. J Clinical Psychiatry, 74(10), 983-90, 2013.

148) Talati A, Wickramaratne PJ, Keyes KM, Hasin DS, Levin FR, Weissman MM. Smoking and psychopathology increasingly associated in recent birth cohorts. Drug Alcohol Depend, 133(2), 724-32, 2013.

149) Raby WN, Rubin EA, Garawi F, Cheng W, Mason E, Sanfilippo L, Lord S, Bisaga A, Aharonovich E, Levin F, McDowell D, Nunes EV. A randomized, double-blind, placebo- controlled trials of venlafaxine for the treatment of depressed cocaine-dependent patients. Amer J Addict, 23(1):68-75, 2014.

150) van de Glind G, Konstenius M, Koeter MW, van Emmerik-van Oortmerssen K, Carpentier PJ, Kaye S, Degenhardt L, Skutle A, Franck J, Bu ET, Moggi F, Dom G, Verspreet S, Demetrovics Z, Kapitány-Fövény M, Fatséas M, Auriacombe M, Schillinger A, Møller M, Johnson B, Faraone SV, Ramos-Quiroga JA, Casas M, Allsop S, Carruthers 39

S, Schoevers RA, Wallhed S, Barta C, Alleman P; IASP Research Group, Levin FR, van den Brink W. Variability in the prevalence of adult ADHD in treatment seeking substance abuse disorder patients: Results from an international multi-center study exploring DSM-IV and DSM-5 criteria. Drug Alcohol Depend, 134:158-166, 2014.

151) Van Emmerik-van Oortmerssen K, van de Glind G, Koeter M, Allsop S, Auriacombe M, Barta C, Bu ET, Burren Y, Carpentier PJ, Surruthers S, Casas M, Demetrovic Z, Dom G, Faraone S, Fatseas M, Franck J, Johnson B, Kapitany-Foveny M, Kaye S, Konstenius, Levin FR, Moggi F, Ramos-Quiroga A. Psychiatric comorbidity in treatment seeking substance use disorder patients with and without ADHD: results of the IASP study. Addiction, 109(2): 262-272, 2014.

152) Dakwar E, Anerella C, Hart CL, Levin FR, Mathew SJ, Nunes EV. Therapeutic infusion of ketamine: Do the psychoactive effects matter? Drug Alcohol Depend, 1;136: 153- 157, 2014.

153) Bisaga A, Sullivan MA, Glass A, Mishlen K. Carpenter KM, Mariani JJ, Levin FR, Nunes EV. A placebo-controlled trial of memantine as an adjunct to injectable extended- release naltrexone for opioid dependence. J Subst Abuse Treat, 46(5): 546-552, 2014

154) Kosten TR, Domingo CB, Shorter D, Orson F, Green C, Somoza E, Sekerka R, Levin FR, Mariani JJ, Stitzer M, Tompkins DA, Rotrosen J, Thakkar V, Smoak B, Kampman K. Vaccine for cocaine dependence: A randomized double-blind placebo-controlled efficacy trial. Drug Alcohol Depend, 140: 42-47, 2014.

155) Dakwar E, Levin FR, Olfson M, Wang S, Kerridge B, Blanco C. First Treatment Contact for ADHD: Predictors of and Gender Differences in Treatment Seeking. Psychiatr Serv. 65(12): 1465-73, 2014.

156) Mariani JJ, Pavlicova M, Mamczur AK, Bisaga A, Nunes EV, Levin FR. Open-label pilot study of quetiapine treatment for cannabis dependence. Am J Drug Alcohol Abuse, 40(4):280-284, 2014.

157) Roebke PV, Vadhan NP, Brooks DJ, Levin FR. Verbal learning in marijuana users seeking treatment: a comparison between depressed and non-depressed samples. Am J Drug Alcohol Abuse, 40(4):274-279, 2014.

158) Hogue A, Bobek M, Tau GZ, Levin FR. Clinical Strategies for Integrating Medication Interventions into Behavioral Treatment for Adolescent ADHD: The Medication Integration Protocol. Child Fam Behav Ther, 36(4): 280-304, 2014.

159) Kelly MA, Pavlicova M, Glass A, Bisaga A, Sullivan MA, Nunes EV, Mariani JJ, Levin FR. Do withdrawal symptoms scores mediate increased marijuana smoking in individuals treated with venlafaxine XR? Drug Alcohol Depend, 144:42-46, 2014.

160) Mariani JJ, Khantzian EJ, Levin FR. The self-medication hypothesis and psychostimulant treatment of cocaine dependence: an update. Am J Addict; 23(2):189- 93, 2014.

161) McClure EA, Sonne SC, Winhusen T, Carroll KM, Ghitza UE, McRae-Clark AL, Matthews AG, Sharma G, Van Veldhuisen P, Vandrey RG, Levin FR, Weiss RD, Lindblad R, Allen C, Mooney LJ, Haynes L, Brigham GS, Sparenborg S, Hasson AL, 40

Gray KM. Achieving Cannabis Cessation - Evaluating N-acetylcysteine Treatment (ACCENT): Design and implementation of a multi-site, randomized controlled study in the National Institute on Drug Abuse Clinical Trials Network. Contemp Clin Trials, 39(2):211-223, 2014.

162) Luo SX, Covey LS, Hu MC, Levin FR, Nunes EV, Winhusen TM. Toward personalized smoking-cessation treatment: Using a predictive modeling approach to guide decisions regarding stimulant medication treatment of attention-deficit/hyperactivity disorder (ADHD) in smokers. Am J Addict, 24(4): 348-356, 2015.

163) Hien DA, Levin FR, Ruglass LM, López-Castro T, Papini S, Hu MC, Cohen LR, Herron A. Combining Seeking Safety With Sertraline for PTSD and Alcohol Use Disorders: A Randomized Controlled Trial. J Consult Clin Psychol, 83(2): 359-369, 2015.

164) Sullivan MA, Bisaga A, Glass A, Mishlen K, Pavlicova M, Carpenter KM, Mariani JJ, Levin FR, Nunes EV. Opioid use and dropout in patients receiving oral naltrexone with or without single administration of injection naltrexone. Drug Alcohol Depend, 147: 122-129, 2015.

165) Levin FR, Mariani JJ, Specker S, Mooney M, Mahony A, Brooks DJ, Babb D, Bai Y, Eberly LE, Nunes EV, Grabowski J. Extended Release Mixed Amphetamine Salts for Comorbid Adult Attention-Deficit/Hyperactivity Disorder and Cocaine Use Disorder: A Randomized Double-blind, Placebo-Controlled Trial. JAMA Psychiatry, 72(6): 593-602, 2015.

166) Wapp M, van de Glind , van Emmerik-van Oortmerssen K, Dom G, Verspreet S, Carpentier PJ, Ramos-Quiroga JA, Skutle A, Bu ET, Franck J, Konstenius M, Kaye S, Demetrovics Z, Barta C, Fatseas M, Auriacombe M, Johnson B, Faraone SV, Levin FR, Allsop S, Carruthers S, Schoevers RA, Koeter MWJ, van de Brink W, Moggi F, IASP Research Group. Risk factors for borderline personality disorder in treatment seeking patients with a substance use disorder: An international multicenter study. Eur Addict Res, 21: 188-194, 2015.

167) Mooney ME, Herin DV, Specker S, Babb D, Levin FR, Grabowski J. Pilot study of the effects of lisdexamfetamine on cocaine use: A randomized, double-blind, placebo- controlled trial. Drug Alcohol Depend, 153: 94-103, 2015.

168) Velez-Pastrana MC, Gonzalez RA, Cardona JR, Baera PP, Rodriguez AA, Levin, FR. Psychometric properties of the Barkley Deficits in Executive Functioning Scale: A Spanish-language version in a community sample of Puerto Rican adults. Psychol Assess. 2015 Aug 24. [Epub ahead of print]

169) Bisaga A, Sullivan MA, Glass A, Mishlen K, Paulicova M, Haney M. Raby WN, Levin FR, Carpenter KM, Mariani JJ, Nunes EV. The effects of dronabinol during detoxification and the initiation of treatment with extended release naltrexone. Drug Alcohol Depend, 154:3 38-45, 2015.

170) Gonzalez R, Velez-Pastrana MC, Correa-Fernandez V, Albizu-Garcia C, Levin FR. Review of the comorbidity of attention-deficit/hyperactivity disorder and substance use disorders in incarcerated populations: Implications for research and intervention. Accepted: Clinical Psychology Review

171) Murray A, Levin FR, Mariani JJ, Brooks D, Glass A, Xie S. Higher Cotinine Levels among non-cigarette smoking blunt and joint user. (Submitted)

172) Carpenter KM, Kulesza M, Curtiss L, Bond F, Levin FR, Nunes EV. Experiential avoidance: a psychometric investigation of the AAQ-II and its association with illicit substance use (Submitted)

173) Moggi F, van de Glind G, Konstenius M, Koeter MW, van Emmerik-van Oortmerssen K, Carpentier PJ, Kaye S, Degenhardt L, Skutle A, Franck J, Bu ET, Moggi F, Dom G, Verspreet S, Demetrovics Z, Kapitány-Fövény M, Fatséas M, Auriacombe M, Schillinger A, Møller M, Johnson B, Levin FR. Risk factors for borderline personality disorder in treatment seeking patients with a substance use disorder: An international multicenter study. (Submitted)

174) Gonzalez R, Ruiz Varcarcel JJ, Velez Pastrana MC, Levin FR, Albizu-Garcia CE. Attention-Deficit/Hyperactivity Disorder in a Latino adult inmate population: Health risk behaviors, comorbid psychiatric and substance use disorders and criminality outcomes. (In preparation)

BOOK CHAPTERS:

1) Levin FR and Kleber HD: Overview of treatment for drug abuse. In: Encyclopedia of Drugs and Alcohol. JH Jaffe, ed. New York, MacMillan, 1995.

2) Levin FR and Kleber HD: Pharmacotherapy of addiction: Introduction and principles. In: Handbook of Experimental Pharmacology: Pharmacological Aspects of Drug Dependence, Volume 118. CR Schuster, SW Gust, and MJ Kuhar, eds., Springer- Verlag, Berlin, 1996.

3) Levin FR, Foltin RW, Fischman MW: Pattern of cocaine use in methadone-maintained individuals applying for research studies. In: The Neurobiology of Cocaine Addiction. H Joseph and B Stimmel, eds., Haworth Medical Press, New York 1997.

4) Levin FR and Donovan S: Attention-deficit/hyperactivity disorder, intermittent explosivedisorder, and eating disorders. In: Principles of Addiction Medicine: American Society of Addiction Medicine, 2nd Edition. AW Graham,TK Schultz, eds. American Society of Addiction Medicine, Chevy Chase, MD, 1029-1046, 1998.

5) Levin FR and Kleber HD: Alcohol and Substance Abuse Disorders. In: Psychiatry. ER Marcus, J Cutler, eds. Philadelphia: W.B. Saunders Company, Harcourt Brace Johanovich, Inc., 128-148, 1999.

6) Levin FR, Kleber HD: Drug abuse-overview and new research directions. Edited by: Helmchem H, Henn F, Lauter H, Sartorious N, In: Psychiatrie der Gegenwart, Springer- Verlag, Berlin, 2001, Part 2, 323-338.

7) Levin FR and Kleber HD: Drug abuse-overview and new research directions In: Contemporary Psychiatry, Volume 3: Specific Psychiatric Disorders. F Henn, N Sartorius, H Helmchen, H Lauter,eds. Berlin, Springer-Verlag (2001). Part 2, 323-338.

8) Sullivan M and Levin FR: Attention-Deficit/Hyperactivity Disorder and Substance Abuse: Diagnostic and Therapeutic Considerations. Adult Attention Deficit Disorder: 42

Brain Mechanisms and Life Outcomes In: J Wasserstein, LE Wolf, and FF Lefever. Annals of the New York Academy of Sciences 931: 251-270, 2001.

9) Levin FR, Sullivan MA, Donovan SJ: Attention-deficit/hyperactivity disorder and Eating Disorders. In: Principles of Addiction Medicine: American Society of Addiction Medicine, 3rd Edition. AW Graham, TK Schultz, MF Mayo-Smith, RK Ries, BB Wilford, eds. American Society of Addiction Medicine, Chevy Chase MD , 1321- 1346, 2003.

10) Levin, FR, Gunderson EW, Levounias, P: Medical Education In: Textbook of Substance Abuse Treatment, M Galanter, HD Kleber, eds. American Psychiatric Publishing, Washington, D.C. 597-609, 2004.

11) Nickita ML and Levin FR: Drug Abuse. In: Conn’s Current Therapy. RE Rakel, ET Bope. WB Saunders Co., NY 1145-1150, 2004.

12) Levin FR: Career Awards (K Series Award Mechanisms). Applying for Training Awards. In: The Complete Writing Guide to NIH Behavioral Science Grants. LM Scheier, ed. Oxford University Press, New York, NY, 225-266, 2007

13) Raby W, Levin FR, Nunes E. Pharmacological Treatment of Substance Abuse. In: Psychiatry Third Edition. A Tasman, J Kay, JA Lieberman, MB First, M Maj, ed. John Wiley & Sons, Ltd, The Atrium, Southern Gate, Chichester, UK, 2390-2416, 2008.

14) Nordstrom B, Levin FR. Substance Abuse: Cannabis-Related Disorder. In: Psychiatry Third Edition. In: Psychiatry Third Edition. A Tasman, J Kay, JA Lieberman, MB First, M Maj, ed. John Wiley & Sons, Ltd, The Atrium, Southern Gate, Chichester, UK, 1041-1057, 2008.

15) Gunderson E, Levin FR. Medical Education In: Textbook of Substance Abuse Treatment, M Galanter, HD Kleber, eds. America Psychiatric Publishing Washington, D.C., 665-680, 2008.

16) Bryan, BR, Levin, FR. Alcohol and Substance Use Disorders. In : Psychiatry. J Cutler, ER Marcus, eds. Oxford University Press, New York, NY, 210-263, 2010.

17) Mariani JJ, Levin FR. Substance Dependence and Co-Occurring Psychiatric Disorders: Best Practices for Diagnosis and Treatment. Edited by Nunes EV, Selzer J, Levounis P, Davies C. In: Substance Abuse and Adult Attention Deficit Hyperactivity Disorder, Civic Research, 5/1-5/18, 2010

18) Levin FR, Sullivan MA, Mariani JJ: Co-Occurring addictive disorder and attention deficit/hyperactivity disorder. In: Principles of Addiction Medicine: American Society of Addiction Medicine, 4th Edition, 1211-1226, 2011.

19) Mariani JJ, Levin FR. Psychostimulant treatment of cocaine dependence. In: Psychiatric Clinics of North America. I Danovitch, JJ Mariani, Eds. W.B. Sanders Company, Philadelphia, PA, 425-439, 2012.

20) Nunes EV, Levin FR: Depression in the context of alcoholism and other substance use disorders. In Handbook for the Management of Mood Disorders. J Mann, S Roose, PJ McGrath, Eds. Cambridge University Press, 234-244, 2013. 43

21) Mariani JJ, Levin FR. Cannabis Dependence. In: Clinical Manual of Addiction Psychopharmacology. HR Kranzler, HD Kleber, C O’Brien eds. American Psychiatric Publishing, Washington, DC, 137-162, 2014

22) Gray K, Levin FR. Marijuana. In: Treatment of Psychiatric Disorders, DSM-5 Edition, G.O. Gabbard, ed. America Psychiatric Publishing Washington, D.C., 841-850, 2014.

23) Levin FR, Kleber HD, Galanter M. Substance Related and Addictive Disorders, Section Editors. In: Treatment of Psychiatric Disorders, DSM-5 Edition, G.O. Gabbard, ed. America Psychiatric Publishing Washington, D.C., 773-778, 2014,

24) Bryan B, Levin FR. Substance related and addictive disorders. In: Psychiatry, Edited by JL Cutler, Oxford University Press, 204-256, 2014.

25) Kelly M, Levin, FR. Treatment of Marijuana Dependence. In: Textbook of Substance Abuse Treatment, M Galanter, HD Kleber, KT Brady, eds. America Psychiatric Publishing Washington, D.C., 351-361, 2014.

26) Gunderson EW, Levin FR, Levounis P. Medical Education in Addiction. In: Textbook of Substance Abuse Treatment, M Galanter, HD Kleber, KT Brady, eds. America Psychiatric Publishing Washington, D.C., 757-770, 2014.

27) Levin FR, Mariani JJ: Co-Occurring addictive disorder and attention deficit/hyperactivity disorder. In: Principles of Addiction Medicine: American Society of Addiction Medicine, 5th Edition. RK Ries, DA Fiellin, SC Millier R Saitz, eds. Wolters Kluwer, Baltimore, MD, 1365-1384, 2014.

28) Levin FR, Mariani JJ. ADHD and Substance Abuse. In: Textbook of Addiction Treatment International Perspective, Volume 1, N El-Guebaly, G. Carra, M. Galanter, eds. Springer Reference, Italia, 2035-2062.

29) Murray A, Levin FR. Marijuana. In: Clinical Textbook of Addictive Disorders, eds. A Mack, K Brady, S.L. Miller, R Frances. Guilford Press, 2015.

30) Raby WN, Mariani JJ, Levin FR, Nunes EV. Pharmacological Treatment of Substance Abuse Disorders. In: Psychiatry, 4th Edition, A Tasman, J Lieberman, J Kay, M First, M Riba, eds, Wiley Blackwell (Accepted)

31) Nordstrom B, Levin FR. Substance Abuse: Cannabis-Related Disorder. In Psychiatry, 4th Edition, A Tasman, J Lieberman, J Kay, M First, M Riba, eds, Wiley Blackwell (Submitted)

32) Levin FR, Mariani JJ. Co-Occurring Addictive Disorder and Attention Deficit/Hyperactivity Disorder. In: ASAM Essentials of Addiction Medicine, 2nd Edition, A Herron, eds, SPi Global (Submitted)

GUEST EDITOR:

1) Levin FR, Evans SM, Editors. Coexisting Substance Abuse and Psychiatric Comorbidity. Psychiatric Annals, Volume 31, Nos. 4 and 5, 2001. 44

2) Dakwar E, Levin FR, Editors. Substance Use and Related Disorders. Current Psychiatry Reports, Volume 17 & 18, 2016.

LETTERS:

1) Gingrich JA, Rudnick-Levin F, Almeida C, Innes L, Schneier H. Cocaine and catatonia. Letter to the Editor. Am J Psychiatry 115:1629, 1998.

2) Mariani JJ, Levin FR. Quetiapine Treatment of Zolpidem Dependence. Am J Addict 16(5): 426, 2007.

3) Levin FR, Mariani JJ, Bisaga A, Nunes EV. Sustained-release methylphenidate in a randomized trial of treatment of methamphetamine use disorder. Letter to Editor. Addiction, 110(5): 875-876, 2015.

ABSTRACTS:

1) Weddington WW and Levin FR: Substance abuse consult service as a method to teach medical students and housestaff. Presented at Association for Medical Education and Research in Substance Abuse, Annual Conference, Rockville, November 1989.

2) Levin FR, Weddington WW, Haertzen C, Cohen A, McDuff DR: A substance use consultation service: characteristics and pedagogical potential. American Psychiatric Association Annual Meeting, NY, 1990, p. 101.

3) Levin FR, Weddington WW, Haertzen C, Cohen A, and McDuff DR: Characteristics of a substance abuse consultation service. Committee on Problems of Drug Dependence 1990: 52nd Annual Meeting, NIDA Research Monograph 1991, p. 291.

4) Levin FR, Hess J, Gorelick DA, Fudala PJ: Patterns of use among cocaine users. Committee on Problems of Drug Dependence 1991: 53rd Annual Meeting, NIDA Research Monograph 1992, p. 439.

5) Levin FR, Foltin RW, Fischman MW: Effects of cocaine on autonomic functioning in humans. Committee on Problems of Drug Dependence 1993: 54th Annual Meeting, Toronto, p. 231.

6) Montoya ID, Levin FR, Fudala PJ, Gorelick DA: Randomized double-blind clinical trial with carbamazepine versus placebo for treatment of cocaine dependence. Committee on Problems of Drug Dependence 1993: 54th Annual Meeting, Toronto, p. 435.

7) Foltin RW, Levin FR, Fischman MW: Effects of cocaine in humans on methadone maintenance. American College of Neuropsychopharmacology, 32nd Annual Meeting, Oahu, HI, December 1993, p. 170.

8) Montoya ID, Levin FR, Fudala PJ, Gorelick DA: Double-blind study with arbamazepine for treatment of cocaine dependence. American College of Neuropsychopharmacology, 32nd Annual Meeting, Oahu, HI, December 1993, p. 173.

9) Evans SM, Foltin RW, Levin FR, Fischman MW: Behavioral and subjective effects of N-2327 (Pazinaclone) and alprazolam in normal volunteers. American College of Neuropsychopharmacology, 33rd Annual Meeting, San Juan, PR, December 1994. 45

10) Levin FR, Foltin RW, Fischman MW: Pattern of cocaine use in methadone maintained individuals. Committee on Problems of Drug Dependence 1994: 56th Annual Meeting, West Palm Beach, FL, p. 16.

11) Foltin RW, Fischman MW, Levin FR, Couraud A, Christiansen I: Effects of acute and repeated intravenous cocaine in humans maintained on methadone. Committee on Problems of Drug Dependence 1994: 56th Annual Meeting, West Palm Beach, FL, p.221.

12) Levin FR, Cutler J, Regent N: Substance abuse attitudes: differences between medical and nursing students. Association for Medical Education and Research in Substance Abuse National Conference: November 9-11, 1995, Washington, D.C., p. 26.

13) Levin FR, Fischman MW, Christiansen I, Foltin RW: A Protocol to Switch High-Dose Methadone Subjects to Buprenorphine. American Academy of Psychiatrists in Alcoholism and Addictions. December 1, 1995, Jacksonville, p. 7.

14) Levin FR, Evans SM, Collins E, Coomaraswamy S, Regent ND, Kleber HD: Flupenthixol treatment for cocaine abusers with schizophrenia. American College of Neuropsychopharmacology 1995: 34th Annual Meeting, San Juan, p. 193.

15) Evans SM, Haney MJ, Levin FR, Foltin RW, Fischman MW: Behavioral and Subjective Effects of Alprazolam in women suffering from premenstrual syndrome. American College of Neuropharmacology 1995: 34th Annual Meeting, San Juan, p. 148.

16) Levin FR, Evans SM, Lugo L, Seham JC, Miller S, Kleber HD: Prevalence of attention- deficit disorders among cocaine abusers. College on Problems of Drug Dependence 1995:57th Annual Meeting, NIDA Monograph 162, Scottsdale, p.317, 1996.

17) Fischman MW, Foltin RW, Levin FR, Christiansen I. Cocaine use by opiate dependent humans: effects of buprenorphine or methadone maintenance. Committee on Problems of Drug Dependence 1995: 57th Annual Meeting, NIDA Monograph, Scottsdale p.201, 1996.

18) Hien DA, Nunes EV, Levin FR: Violence, psychiatric comorbidity and gender: Predictors of outcome in methadone patients. Committee on Problems of Drug Dependence 1995:Committee on Problems of Drug Dependence 1995: 57th Annual Meeting, NIDA Monograph 162, Scottsdale, p. 331, 1996.

19) Levin FR, Evans SM, Yuan H, Rhum M, Regent ND, Kleber HD. Methylphenidate treatment of cocaine-abusing adults with ADHD. American Psychiatric Association 1996: Annual Meeting, New York, p.141.

20) Levin FR, Evans SM, Lugo L, Seham JC, Baird D, Kleber HD. ADHD in cocaine abusers: psychiatric comorbidity and pattern of drug use. College on Problems of Drug Dependence 1996: 58th Annual Meeting, Puerto Rico, p. 124.

21) Evans SM, Levin FR: Effects of alprazolam and buspirone in women with a family history of alcoholism. American College of Neuropsychopharmacology 1996, 35th Annual Meeting, San Juan, poster. 46

22) Evans SM, Haney MJ, Levin FR, Foltin RW, Fischman MW: Menstrual cycle effects in women with premenstrual syndrome. Journal European College of Neuropharmacology 6 (suppl 3): 57, 1996.

23) Levin F, Evans SM, Rosenthal M, and Kleber HD: Psychiatric comorbidity in cocaine abusers in outpatient settings or a therapeutic community: Psychiatric Comorbidity in Drug Abusers. College on Problems of Drug Dependence 1997: 59th Annual Meeting, Nashville TN, p.132.

24) Rabinowitz E, Pace NA, Levin FR, Owen P: The physicians in residence program- Hazelden New York. J Addictive Disease 16:A 33, 1997.

25) Levin F, Owen P, Stinchfield R, Rabinowitz E, Pace NA: Physicians in Residence Program: Evaluation of a Substance Abuse Training Approach Using Simulated Patients. American Psychiatric Association 1997: Annual Meeting, New York, p. 156.

26) Evans SM, Levin FR, and Foltin RW: Methods for Increasing Female Study Participation and Studying Cocaine Abstinence. College on Problems of Drug Dependence 1997:59th Annual Meeting, NIDA Monograph, Nashville, TN, p. 334.

27) McDowell DM, Levin FR, Seracini A, and Nunes EV: Venlafaxine in the Treatment of a Population with Major Depression and Cocaine Dependence, College on Problems of Drug Dependence 1997:59th Annual Meeting, NIDA Monograph, Nashville, TN, p. 255.

28) Levounis P, Levin FR, and Kleber HD: “Frequent fliers” in an urban emergency room, American Academy of Addiction Psychiatry 1997: 8th Annual Meeting, Final Program and Abstracts, p.24.

29) Evans SM, Levin FR, and Kleber HD: The effects of cocaine alone and in combination with sustained-release methylphenidate in cocaine abusers with ADHD, American College of Neuropharmacology 1997:36th Annual Meeting, Scientific Abstracts, p. 211.

30) Evans SM, Levin FR. Effects of alprazolam in women: Differences as a function of a paternal history of alcoholism. Poster, Congress on Women’s Health, Washington, DC, June, 1997.

31) Sullivan MA, Levin FR, Coomaraswamy S, Fischman MW: Patterns of smoking among schizophrenic and schizoaffective patients. National Society for Research on Nicotine and Tobacco March 1998: Annual Meeting, Scientific Abstracts.

32) Sullivan MA, Levin FR, Coomaraswamy S, Fischman MW. Patterns of nicotine use among outpatients with schizophrenia or schizoaffective disorder. College on Problems of Drug Dependence 1998: 60th Annual Meeting, Scottsdale, AZ.

33) Evans SM, Levin FR. Increased sensitivity to alprazolam in women with a paternal history of alcoholism. Problems of Drug Dependence 1998: Proceedings of the 60th Annual Meeting, Scottsdale, AZ, p. 264.

34) Levin FR, Evans SM, McDowell DM, Kleber HD, Brooks DM, Rhum M and Kleber HD. Bupropion Treatment for Adult ADHD and Cocaine Abuse. Problems of Drug Dependence 1998: Proceedings of the 60th Annual Meeting, Scottsdale, AZ, p. 209. 47

35) Levin FR, Evans SM, Kleber HD. Bupropion Treatment for Cocaine Abusers with Adult- Attention-Deficit/Hyperactivity Disorder. Problems of Drug Dependence 1998: Proceeding of the 60th Annual Meeting, Scottsdale, AZ, p.39.

36) Donaldson P, Levin, FR, Evans, S, Kleber HD. Treatment Outcomes of Cocaine Abusers Seeking Treatment in a Therapeutic Community: Impact of Psychiatric Comorbidity. American Academy of Addiction Psychiatry 1998: 9th Annual Meeting, Amelia Island, Program Abstracts, p.19.

37) Sullivan MA, Levin FR, Coomaraswamy S, Fischman MW: Patterns of smoking among schizophrenic and schizoaffective patients. National Society for Research on Nicotine and Tobacco March 1998: Annual Meeting, Scientific Abstracts.

38) Donaldson P, Levin, FR, Evans, S, Kleber HD. Treatment Outcomes of Cocaine Abusers Seeking Treatment in a Therapeutic Community: Impact of Psychiatric Comorbidity. American Academy of Addiction Psychiatry 1998: 9th Annual Meeting, Scientific Abstracts, p. 19.

39) Evans SM, Levin FR. The effects of alprazolam and buspirone in females: Comparison of moderate and light social drinkers. American College of Neurophsychopharmacology, Las Croabas PR, December 1998.

40) McDowell, DM, Rothenberg J, Sia A, Nunes EV, Levin FR: Improved Retention Designs for Addiction. American Psychiatric Association Meeting 1999: 152nd Annual Meeting, Washington, D.C., Program Abstracts, p. 149.

41) Levin FR, Evans SM, Abi-Darghan A, Kegeles L. Sia A, Zea-Ponce Y, Laruelle M. SPECTImaging of amphetamine-induced dopamine release in cocaine abusers with adult ADHD compared to controls. College on Problems of Drug Dependence 1999: Proceeding of the 61st Annual Meeting, Acapulco MX, p. 103.

42) Akerele E, Levin FR, Nunes E, Brady R, Pierce D, Kleber HD. The effects of triple therapy and gender on methadone levels in methadone maintained patients. College on Problems of Drug Dependence 1999: Proceeding of the 61st Annual Meeting, Acapulco MX, p. 179.

43) Donaldson PL, Levin FR, Juliana P, Figueroa L. Employability of methadone-maintained women. College on Problems of Drug Dependence 1999: Proceeding of the 61st Annual Meeting, Acapulco MX, p 222.

44) Evans SM, Levin FR. The effects of alcohol in females with and without a paternal history of alcoholism. College on Problems of Drug Dependence 1999: Proceeding of the 61st Annual Meeting, Acapulco MX, p. 179.

45) Sullivan MA, Levin FR, Cooaraswammy S, Fischman MW, Covey LS. A smoking cessation trial in schizophrenic and schizoaffective outpatients. College on Problems of Drug Dependence 1999: Proceeding of the 61st Annual Meeting, Acapulco MX, p 105.

46) Brooks DJ, Levin FR, Evans SM, Nunes E, Sia A. Cognitive functioning in methadone patients: the effects of cocaine and ADHD. College on Problems of Drug Dependence

2000: Abstracts for the 62nd Annual Scientific Meeting, June 17-22, 2000, San Juan, PR. In Drug Alc Depend 60, Suppl. No. 1, S25.

47) Levin FR, McDowell D, Evans SM, Akarele E, Sia, Donovan S. Treatment of marijuana dependence with divalproex sodium: a preliminary randomized, double-blind, placebo- controlled trial. College on Problems of Drug Dependence: Abstracts for the 62nd Annual Scientific Meeting, June 17-22, 2000, San Juan, PR. In Drug Alc Depend 60, Suppl. No. 1, S125.

48) Akerele E, Lazaridis P, Brady R, Nunes E, Levin FR. Effect of cocaine abuse on treatment outcome in methadone maintained patients. College on Problems of Drug Dependence 2000:Abstracts for the 62nd Annual Scientific Meeting, June 17-22, 2000, San Juan, PR. In Drug Alc Depend 60, Suppl. No. 1, S3. 2000: Drug Alc Depend 60, Suppl. No. 1, S3.

49) Evans SM, Levin FR, Foltin RW. The effects of alprazolam in depressed women. American College of Neuropsychopharmacology, Dec 2000.

50) Wilson JJ, Levin FR, Donovan SJ. Linguistic predictors of attrition from an adolescent therapeutic community: a pilot study. American Society of Addiction Medicine 32nd Annual Medical-Scientific Conference, April 19-22, 2001, Los Angeles.

51) Akerele E, Nunes E, Brady R, Levin F. Role of HIV medications in methadone- maintained patients. College on Problems of Drug Dependence 2001: Abstracts for the 63rd Annual Scientific Meeting, June 16-21, 2001, Scottsdale, AZ. Drug Alc Depend 63: S5, 2001.

52) Miele GM, Litt LC, Hien DA, Levin FR. Putting science into practice : Utilizing research protocols to treat women with addictions and co-morbid PTSD in a community treatment program. College on Problems of Drug Dependence 2001: Abstracts for the 63rd Annual Scientific Meeting, June 16-21, 2001, Scottsdale, AZ. Drug Alc Depend 63: S106, 2001.

53) Sullivan MA, Levin FR. Parameters of smoking status among smoking cessation seeking schizophrenic/schizoaffective patients. College on Problems of Drug Dependence 2001: Abstracts for the 63rd Annual Scientific Meeting, June 16-21, 2001, Scottsdale, AZ. Drug Alc Depend 63:S154, 2001.

54) Levin, F.R., Evans, S.M., Sullivan, M. and Brooks, D. Pattern of drug use among methadone-maintained patients: Individuals with and without adult attention-deficit hyperactivity disorder (ADHD). College on Problems of Drug Dependence 2001: Abstracts for the 63rd Annual Scientific Meeting, June 16-21, 2001, Scottsdale, AZ. Drug and Alcohol Dependence 63:S90, 2001.

55) Brooks DJ, Levin FR, Evans SM. Detecting adult ADHD in methadone-maintained patients: Diagnostic utility of the Wender Utah Rating Scale and the adult ADHD rating scale. College on Problems of Drug Dependence 2001: Abstracts for the 63rd Annual Scientific Meeting, June 16-21, 2001, Scottsdale, AZ. Drug and Alcohol Dependence 63:S20, 2001.

56) Evans SM, Foltin RW, Levin FR. The effects of alcohol in females with and without a paternal history of alcoholism. Alcoholism: Clin Exp Res 25:5S 139A, 2001.

57) Wilson J, Levin FR, Donovan S. Linguistic predictors of attrition from a therapeutic community. American Academy of Child and Adolescent Psychiatry. Oct 27th, 2001, Honolulu, Hawaii.

58) Gunderson EW, Levin FR, Smith L. A survey of internal medicine interns and residents on the diagnosis and management of substance abuse. Abstracts for American Society of Addiction Medicine 33rd Annual Meeting, April 25-28th, 2002. In J Addictive Diseases 21:118.

59) Levin FR, Evans SM, Brooks D, Sullivan M, Nunes E, Vosburg S. Treatment of adult ADHD in methadone maintenance patients: preliminary findings from a double-blind, three-armed, placebo-controlled trial. . College on Problems of Drug Dependence 2002: Abstracts for the 64rd Annual Scientific Meeting, June 8-13th, 2002, Quebec City, Canada; Drug and Alcohol Dependence 66: S102, 2002.

60) Kalbag, AS, Evans SM, Brooks DJ, Mahoney A, Rothenberg JL, Levin FR. The development of an HIV counseling intervention for methadone-maintained patients: RISE (Reduce high-risk intravenous drug use and unsafe sexual encounters). College on Problems of Drug Dependence 2002: Abstracts for the 64rd Annual Scientific Meeting, June 8-13th, 2002, Quebec City, Canada; Drug and Alcohol Dependence 66: S89, 2002.

61) Brooks DJ, Kalbag AS, Evans SM, Rothenberg JL, Clodfelter T, Levin FR. HIV and hepatitis risk assessment in methadone-maintained patients with adult ADHD: are they at higher risk? College on Problems of Drug Dependence 2002: Abstracts for the 64rd Annual Scientific Meeting, June 8-13th, 2002, Quebec City, Canada; Drug and Alcohol Dependence 66: S21, 2002.

62) Clodfelter RC, Aharononvich E, McDowell DM, Vosburg S, Levin FR. Clinical effects of smoked marijuana on cognitive performance. College on Problems of Drug Dependence 2002: Abstracts for the 64rd Annual Scientific Meeting, June 8-13th, 2002, Quebec City, Canada; Drug and Alcohol Dependence 66: S33, 2002.

63) Akerele EO, Gill KB, Vosburg S, Levin FR. Efficacy of atypical neuroleptics in treatment substance use among schizophrenic individuals. College on Problems of Drug Dependence 2002: Abstracts for the 64rd Annual Scientific Meeting, June 8-13th, 2002, Quebec City,Canada; Drug and Alcohol Dependence 66:S4, 2002.

64) Gill KB, Sonpal SB, Akerele EO, Vosburg S, Levin FR. Motivation for treatment: Comparison of marijuana and cocaine-dependent treatment-seeking individuals. College on Problems of Drug Dependence 2002: Abstracts for the 64rd Annual Scientific Meeting, June 8-13th, 2002, Quebec City, Canada; Drug and Alcohol Dependence 66: S64, 2002.

65) Brooks DJ, Brady R, Levin FR. Effect of methadone dose on drug abuse patterns of patients on methadone maintenance. College on Problems of Drug Dependence 2003: Abstracts for the 65th Annual Scientific Meeting, June 14-19th, 2003, Bal Harbour, Florida; Drug and Alcohol Dependence 64: S16, 2003.

66) Han SC, Beck SE, Levin FR, Evans SM. Links between binge-drinking behavior and a restrained eating pattern in female social drinkers. College on Problems of Drug Dependence 2002: Abstracts for the 65rd Annual Scientific Meeting, June 14-19th, 2003, Bal Harbour, Florida; Drug and Alcohol Dependence 64: S16, 2003.

67) Kalbag AS, Brooks DJ, Nunes EV, Evans SM, and Levin FR. The relationship between the specific and nonspecific ADHD symptoms and addiction severity in a methadonemaintenance sample of adults with ADHD. College on Problems of Drug Dependence 2003: Abstracts for the 65rd Annual Scientific Meeting, June 14-19th, 2003, Bal Harbour, Florida; Drug and Alcohol Dependence 64: S16, 2003.

68) Levin FR, Evans SM, Horton T, Brooks DJ, Ng J, Vosburg SK. Attention-deficit hyperactivity disorder and other psychopathology as a predictor of treatment retention in a therapeutic community. College on Problems of Drug Dependence 2003: Abstracts for the 65rd Annual Scientific Meeting, June 14-19th, 2003, Bal Harbour, Florida; Drug and Alcohol Dependence 64: S16, 2003.

69) Akerele EO, Biederman L, Lebowitz A, Garawi F, Levin FR. Treatment of cocaine/marijuana abuse among schizophrenic individuals: a look at the efficacy of the atypical neuroleptics, 14th Annual Meeting, New Orleans, Dec 4-7th, 2003.

70) Evans SM, Bruder GE, Sedoruk JP, Levin FR. Family history of alcoholism in women: effects of alprazolam on mood, performance, and EEG across the menstrual cycle. Collegium Internationale Neuro-psychopharmacology, 2003.

71) Gunderson EW, Levin FR, Owen F. Impact of a substance abuse curriculum on medical resident screening: a chart review. Abstracts for American Society of Addiction Medicine 35th Annual Meeting, April 22-25th, 2004.

72) Levin FR, Mariani JJ, Shagrin S, Evans SM. Contingency management for attendance in a pharmacotherapy clinical trial for alcohol dependence. Abstract for College on Problems of Drug Dependence 66th Annual Scientific Meeting, San Juan, Puerto Rico, June 12-17, 2004.

73) Mariani JJ, Haney M, Hart CL, Vosburg SK, McDowell DM, Levin FR. Marijuana smokers: Treatment seekers show more depressive symptoms that non-treatment seekers. Abstract for College on Problems of Drug Dependence 66th Annual Scientific Meeting, San Juan, Puerto Rico, June 12-17, 2004.

74) Kalbag AS, Jung M, Brooks DJ, Straub D, Uba A, Evans SM, Levin FR. The relationship between conduct disorder, antisocial personality disorder, and attention deficit hyperactivity disorder in a methadone-maintained sample. Abstract for College on Problems of Drug Dependence 66th Annual Scientific Meeting, San Juan, Puerto Rico, June 12-17, 2004.

75) Akerele EO, Biderman L, Levin FR. A pilot study of olanzapine/risperidone for the treatment of cocaine/marijuana use disorder in individuals with schizophrenia. Abstract for College on Problems of Drug Dependence 66th Annual Scientific Meeting, San Juan, Puerto Rico, June 12-17, 2004.

76) Gunderson EW, Levin FR, Rombone MM, McDowell DM, Kleber HD. The temporal process of buprenorphine induction at an outpatient clinical program. Abstract for College on Problems of Drug Dependence 66th Annual Scientific Meeting, San Juan, Puerto Rico, June 12-17, 2004.

77) Raby W, Carpenter KM, Nunes EV, Levin FR. Temperament characteristics moderate response to sertraline in depressed opiate-dependent methadone patients. Abstract for 51

College on Problems of Drug Dependence 66th Annual Scientific Meeting, San Juan, Puerto Rico, June 12-17, 2004.

78) Raby WN, Masson E, Garawi F, Bisaga A, Levin FR, Rubin E, McDowell D, Nunes EV. Venlafaxine for the treatment of depressed cocaine abusers. Abstract for College on Problems of Drug Dependence 67th Annual Scientific Meeting, Orlando FL, June 18th- 23rd, 2005.

79) Brooks DJ, Evans SM, Levin FR: A computerized continuous performance task-assessing treatment outcome of adult ADHD in methadone maintenance patients. Abstract for College on Problems of Drug Dependence 67th Annual Scientific Meeting, Orlando FL, June 18th-23rd, 2005.

80) Collins SL, Levin FR, Foltin RW, Evans SM: Effect of oral methylphenidate maintenance on the subjective and cardiovascular effects of cocaine in adults with ADHD. Abstract for College on Problems of Drug Dependence 67th Annual Scientific Meeting, Orlando FL, June 18th-23rd, 2005.

81) Levin FR, Evans SM, Brooks DJ, Garawi F: Treatment of cocaine-dependent treatment seekers with adult ADHD: A double-blind comparison of methylphenidate and placebo. Abstract for College on Problems of Drug Dependence 67th Annual Scientific Meeting, Orlando FL, June 18th-23rd, 2005.

82) Jung M, Brooks DJ, Evans SM, Levin FR: Smoking patterns and attention-deficit hyperactivity disorder symptoms among treatment-seeking cocaine-dependent adults. Abstract for College on Problems of Drug Dependence 67th Annual Scientific Meeting, Orlando FL, June 18th-23rd, 2005.

83) Mariani JJ, Haney M, Hart CL, Levin FR: Timeline follow-back procedure for marijuana: How may joints in a blunt? Abstract for College on Problems of Drug Dependence 67th Annual Scientific Meeting, Orlando FL, June 18th-23rd, 2005.

84) Chicurel M, Brooks DJ, Levin FR. Is pretreatment assessment therapeutic? Change in marijuana use among cannabis-dependent treatment seekers during the clinical trial evaluation period. Abstract for College on Problems of Drug Dependence 68th Annual Scientific Meeting, Scottsdale, AZ, June 17-22, 2006.

85) Garawi F, Bisaga A, Nunes E, Aharonovich E, Raby W, Rubin E, Levin FR. Predictors of treatment outcome among cocaine-dependent individuals. Abstract for College on Problems of Drug Dependence 68th Annual Scientific Meeting, Scottsdale, AZ, June 17- 22, 2006.

86) Levin FR, Mariani J, Hennessy G, Diaz L, Brooks DJ. Atomoxetine treatment of cocaine-dependent adults with ADHD: An open trial. Abstract for College on Problems of Drug Dependence 68th Annual Scientific Meeting, Scottsdale, AZ, June 17-22, 2006.

87) Gunderson EW, Fiellin DA, Levin FR, Sullivan LE, Kleber HD. Evaluation of a buprenorphine training program. Abstract for College on Problems of Drug Dependence 68th Annual Scientific Meeting, Scottsdale, AZ, June 17-22, 2006.

88) Green LL, Horton T, Phillips A, Levin FR, Fullilove R. Prevalence and relationship of overweight and obesity among men and women in a long-term residential substance 52

abuse treatment program. Abstract for College on Problems of Drug Dependence 68th Annual Scientific Meeting, Scottsdale, AZ, June 17-22, 2006.

89) McDowell D, Levin FR, Brooks DJ, Carpenter K, Garawi F. Treatment of cannabis- dependent treatment seekers: A double-blind comparison of nefazodone, bupropion and placebo. Abstract for College on Problems of Drug Dependence 68th Annual Scientific Meeting, Scottsdale, AZ, June 17-22, 2006.

90) Renner JA, Levin FR, Hennessy G, Waldbaum M, Edner B. Psychiatry residents’ narrative responses to addiction psychiatry career survey. Abstract for American Academy of Addiction Psychiatry, 17th Annual Meeting and Symposium, St Pete Beach, FL, December 7-10, 2006.

91) Horey J, Mariani JJ, Bisaga A, Levin FR. Comparison of substance use milestones in cannabis- and cocaine-dependent patients. Abstract for American Academy of Addiction Psychiatry, 17th Annual Meeting and Symposium, St Pete Beach, FL, December 7-10, 2006.

92) Levin FR, Mariani JJ, Chicurel M, Evans SM, Brooks DJ. Utility of a contingency management strategy to improve retention in a pharmacologic treatment trial targeting cannabis dependence. Abstract for College on Problems of Drug Dependence 69th Annual Scientific Meeting, Quebec, Canada, June 16-21, 2007.

93) Gunderson EW, Fiellin DA, Nelson AR, Vosburg SK, Levin FR. Buprenorphine/naloxone maintenance for opioid dependence in primary care. Abstract for College on Problems of Drug Dependence 69th Annual Scientific Meeting, Quebec, Canada, June 16-21, 2007.

94) Shakibaie Smith S, Collins SL, Levin FR, Evans SM. Changes in mood, performance, food craving and food intake across the menstrual cycle in women with premenstrual dysphoric disorder. Abstract for College on Problems of Drug Dependence 69th Annual Scientific Meeting, Quebec, Canada, June 16-21, 2007.

95) Smith BE, Fletcher A, Brooks DJ, Mariani JJ, Levin FR. A comparison on psychosocial functioning and cognitive functioning between depressed and non-depressed patients with marijuana dependence. Abstract for College on Problems of Drug Dependence 69th Annual Scientific Meeting, Quebec, Canada, June 16-21, 2007.

96) Aharonovich E, Bisaga A, Garawi F, Levin FR, Mariani JJ, Nunes EV, Raby W. Behavioral patterns of cocaine use: Treatment implications. Abstract for College on Problems of Drug Dependence 69th Annual Scientific Meeting, Quebec, Canada, June 16- 21, 2007.

97) Mariani JJ, Horey J, Bisaga A, Nunes EV, Aharonovich E, Raby W, Levin FR. Adult antisocial behavior in cocaine and cannabis dependence. Abstract for College on Problems of Drug Dependence 69th Annual Scientific Meeting, Quebec, Canada, June 16- 21, 2007.

98) Nordstrom BR, Mariani JJ, Bisaga A, Nunes EV, Brooks DJ, Levin FR. Effects of a history of violent crime on treatment retention at the Substance Treatment and Research Service of Columbia University. Abstract for College on Problems of Drug Dependence 69th Annual Scientific Meeting, Quebec, Canada, June 16-21, 2007. 53

99) Bisaga A, Aharonovich E, Garawi F, Levin FR, Raby W, Mariani JJ, Nunes EV. Memantine treatment of cocaine dependence. Abstract for College on Problems of Drug Dependence 69th Annual Scientific Meeting, Quebec, Canada, June 16-21, 2007.

100) Mahony A, Brooks DJ, Mariani J, Raby W, DuBose-O’Hagan T, Nunes EV, Sullivan M. Impact of primary drug of abuse on BMI: Baseline and at end of treatment. Abstract for College on Problems of Drug Dependence 70th Annual Scientific Meeting, San Juan, Puerto Rico, June 14-19, 2008.

101) Brooks D, Aharanovich E., Levin FR. Cognitive impairment and treatment retention among cannabis-dependent patients. Abstract for College on Problems of Drug Dependence 70th Annual Scientific Meeting, San Juan, Puerto Rico, June 14-19, 2008.

102) Bryan BR, Brooks DJ, Mariani JJ, Levin FR. HIV risk among treatment-seeking marijuana, cocaine and opioid users. Abstract for College on Problems of Drug Dependence 70th Annual Scientific Meeting, San Juan, Puerto Rico, June 14-19, 2008.

103) Gunderson EV, Ciffin P, Polydorou S, Chang N, Levin FR. Training medical residents to recognize and manage prescription opioid abuser among chronic pain patients. Abstract for College on Problems of Drug Dependence 70th Annual Scientific Meeting, San Juan, Puerto Rico, June 14-19, 2008.

104) Michaels ES, Vadhan NP, Bagenstose MA, Martinez D, Levin FR, Foltin RW, van Gorp WG. Treatment-seeking for cocaine abuse: relationship to executive functioning. Abstract for American Psychological Association, 116th Annual Scientific Meeting, Boston, August 14-17th, 2008

105) Evans SM, Collins Reed S, Levin FR. Childhood sexual abuse: response to alcohol and amphetamine on measures of impulsivity, mood, and performance. American College of Neuropsychopharmacology, 47th Annual Scientific meeting, Scottsdale AZ, December 7th-11th, 2008.

106) Cheng W, Nunes EV, Levin FR, Bisaga A. Assessing the reliability and validity of cocaine use algorithms in clinical trials. The Johns Hopkins Bloomberg School of Public Health Third Annual Conference for the Dissemination of Student Research on Addictions, Infectious Disease, and Public Health. Baltimore, MD, April 24, 2009.

107) Bryan, BR, Gunderson, E, Vosburg, SK, Archibald, L, Levin FR. The relationship between nicotine use and opioid dependence treatment during the early phase of primary care buprenorphine stabilization. College on Problems of Drug Dependence 71st Annual Scientific Meeting, Reno, NV, June 20-25, 2009.

108) Brooks DJ, Evans SM, and Levin FR. Impact of adult ADHD and cocaine dependence on measures of attention and impulsivity. College on Problems of Drug Dependence 71st Annual Scientific Meeting, Reno, NV, June 20-25, 2009.

109) Herin DV, Moukaddam NJ, Schmitz JM, McCleary PM, Rinker DV, Malcolm C, Levin FR, Grabowski J. Development of cognitive behavioral therapy platform targeting both cocaine dependence and ADHD. College on Problems of Drug Dependence 71st Annual Scientific Meeting, Reno, NV, June 20-25, 2009.

110) Bryan, BR, Gunderson, E, Vosburg, SK, Archibald, L, Levin FR. The relationship between nicotine use and opioid dependence treatment during the early phase of primary care buprenorphine stabilization. College on Problems of Drug Dependence 71st Annual Scientific Meeting, Reno, NV, June 20-25, 2009.

111) Mahony AL, Berhane SS, Brooks DJ, Mariani JJ, Levin FR. Utility of various screening instruments for attention-deficit hyperactivity disorder in research participants seeking treatment for cocaine dependence. College on Problems of Drug Dependence 71st Annual Scientific Meeting, Reno, NV, June 20-25, 2009.

112) Mariani JJ, Sullivan M, Bisaga A, Carpenter K, Murray KA, Levin FR. Nunes EV Nunes. Naltrexone-induced protracted opioid withdrawal. College on Problems of Drug Dependence 71st Annual Scientific Meeting, Reno, NV, June 20-25, 2009.

113) Reed SC, Levin FR, Evans SM. The effects of progesterone pretreatment on the response to oral d-amphetamine: Impulsivity, mood and performance. College on Problems of Drug Dependence 71st Annual Scientific Meeting, Reno, NV, June 20-25, 2009.

114) Rothenberg LR, Brooks DJ, Feldman D, Bisaga A, Mariani J, Levin FR. Changes in cigarette use among cocaine abusers in a pharmacological treatment trial. College on Problems of Drug Dependence 71st Annual Scientific Meeting, Reno, NV, June 20-25, 2009.

115) Williams KL, Carpenter KM, Levin FR, Nunes EV. Experiential avoidance predicts substance abuse treatment entry. College on Problems of Drug Dependence 71st Annual Scientific Meeting, Reno, NV, June 20-25, 2009.

116) Wyman BJ, Sanfilippo LC, Brooks DJ, Raby WN, Nunes EV, Mariani JJ, Levin FR. Depressed cocaine-dependent and cannabis-dependent individuals seeking treatment comparison of psychiatric symptomatology. College on Problems of Drug Dependence 71st Annual Scientific Meeting, Reno, NV, June 20-25, 2009.

117) Mahony AL, Berhane SS, Gangoo AK, Brooks DJ, Mariani JJ, Levin FR. Utility of various screening instruments for attention-deficit hyperactivity disorder (ADHD) in research participants seeking treatment for cocaine dependence. American Professional Society of ADHD and Related Disorders (APSARD), Philadelphia, PA, November 13, 2009.

118) Reed SC, Levin, FR, Evans SM. The effects of alcohol on impulsivity, mood and performance in light and moderate female drinkers. Poster, American College of Neuropsychopharmacology, Hollywood, FL, December, 2009

119) Evans, SM, Reed, SC, Levin, FR. Response to alcohol on measures of impulsivity, mood, and performance in women: Role of paternal history of alcoholism. Poster, American College of Neuropsychopharmacology, Hollywood, FL, December, 2009.

120) Dakwar E, Brooks MA, Raby WN, Bisaga A, Sullivan M, Mariani JJ, Levin FR. Mindfulness Ratings in Monosubstance and Polysubstance Dependent Treatment Seekers. American Academy of Addiction Psychiatry 20th Annual Meeting, Los Angeles CA, December 3-6, 2009.

121) Gunderson EW, Wang XQ, Fiellin DA, B Bryan, Levin FR. Observed versus observed office buprenorphine/naloxone induction: A pilot randomized clinical trial. American Society of Addiction Medicine 41st Annual Meeting, San Francisco, CA, April 15-18, 2010.

122) Cheng WY, Nunes E, Levin FR, Bisaga A, Assessing the reliability and validity of cocaine use algorithms in clinical trials. College on Problems of Drug Dependence 72nd Annual Scientific Meeting, Scottsdale, AZ, June 12-17, 2010.

123) Roebke P, Vadhan, NP, Brooks DJ, Levin FR. Marijuana use patterns, but not depressive symptoms are associated with verbal learning and memory function in marijuana- dependent individuals in treatment. College on Problems of Drug Dependence 72nd Annual Scientific Meeting, Scottsdale, AZ, June 12-17, 2010.

124) Gunderson EW, Wang XQ, Fiellin DA, Bryan B, Levin FR. Unobserved versus office buprenorphine/naloxone induction: A pilot randomized clinical trial. College on Problems of Drug Dependence 72nd Annual Scientific Meeting, Scottsdale, AZ, June 12- 17, 2010.

125) Kirkpatrick MG, Gunderson EW, Johanson CE, Levin FR, Foltin RW, Hart CL. Effects of intranasal d-amphetamine and methamphetamine administration in humans. College on Problems of Drug Dependence 72nd Annual Scientific Meeting, Scottsdale, AZ, June 12-17, 2010.

126) Dakwar E, Levin FR. A comparison of independent and substance-induced depression in cannabis-, cocaine-, and opioid-dependent treatment seekers. College on Problems of Drug Dependence 72nd Annual Scientific Meeting, Scottsdale, AZ, June 12-17, 2010.

127) Dakwar E, Mariani J, Nunes EV, Levin FR. Mindfulness-based psychotherapy for cannabis or cocaine dependence. College on Problems of Drug Dependence 73rd Annual Scientific Meeting, Hollywood, FL, June 18-23, 2011.

128) Mariani JJ, Cheng W, Pavlicova M, Bisaga A, Nunes EV, Brooks D, Levin FR. Extended-release mixed amphetamine salts and topiramate increase abstinence rates in cocaine-dependent individuals. College on Problems of Drug Dependence 73rd Annual Scientific Meeting, Hollywood, FL, June 18-23, 2011.

129) Miner JL, Roebke P, Brooks DJ, Mariani JJ, Levin FR. Effects of chronic nicotine use on cocaine use. College on Problems of Drug Dependence 73rd Annual Scientific Meeting, Hollywood, FL, June 18-23, 2011.

130) Tau G, Torres-Sanchez T, Horga G, Graniello B, Randolph K, Wang Z, Levin FR, Peterson B. Neural correlates of self-regulatory control in cannabis using youth. 66th Annual Meeting for the Society of Biological Psychatry, San Francisco, May , 2011

131) Kirkpatrick MG, Gunderson EW, Levin FR, Foltin RW, Hart CL. Acute and residual interactive effects of repeated administration of oral methamphetamine and alcohol in humans. College on Problems of Drug Dependence 73rd Annual Scientific Meeting, Hollywood, FL, June 18-23, 2011.

132) Reed SC, Levin FR, Evans SM. Sex differences in the effects of oral d-amphetamine on impulsivity, mood and performance in normal healthy controls. College on Problems of Drug Dependence 73rd Annual Scientific Meeting, Hollywood, FL, June 18-23, 2011.

133) Mooney M, Levin FR. Babb D, Brooks D, Mahony A, Grabowski J. Attention-deficit/ hyperactivity disorder subtypes in cocaine-dependent individuals: Frequency and characteristics. College on Problems of Drug Dependence 73rd Annual Scientific Meeting, Hollywood, FL, June 18-23, 2011.

134) Brooks DJ, Mariani JJ, Levin FR. Impact of cigarette use on treatment outcome in blunt smokers and other cannabis users in a cannabis-dependent sample. College on Problems of Drug Dependence 73rd Annual Scientific Meeting, Hollywood, FL, June 18-23, 2011.

135) Mamczur AK, Mariani JJ, Brady R, Nunes EV, Levin FR. Benzodiazepine use in methadone maintenance treatment patients. College on Problems of Drug Dependence 73rd Annual Scientific Meeting, Hollywood, FL, June 18-23, 2011.

136) Michaels E, Vadhan NP, Reed SC, Raby WN, Levin FR, Foltin RW. Decision-making in cocaine abusers: Relationship to treatment-seeking for cocaine dependence. American Psychological Association 119th Annual Convention, Washington, DC, August 4-7, 2011.

137) Levin FR. How to write a grant application: The next step toward an independent research career. NIDA Grant Writing Workshop at the College on Problems of Drug Dependence 73rd Annual Scientific Meeting, Hollywood, FL, June 21, 2011.

138) Gonzalez RA, Ruiz Varcarcel JJ, Levin FR, Albizu-Garcia CE. Profile of Puerto Rican Inmates with Attention-Deficit/Hyperactivity Disorder: Health history, psychiatric comorbidity, substance use disorders and criminality outcomes. ADHD Federation, Berlin, Germany, 2011.

139) Tau GZ, Torres-Sanchez T, Randolph K, Horga G, Graniello B, Wang Z, Levin FR, Peterson B. Self Regulatory Control in Cannabis-Using Youth: an fMRI Study. Society of Biological Psychiatry 67th Annual Conference, Philadelphia, PA, May 3-5, 2012.

140) Gregory Tau, Tania Torres-Sanchez, Guillermo Horga, Barbara Graniello, Zhishun Wang, Frances Levin, Bradley Peterson An fMRI Study Of Self-Regulatory Control In Cannabis Using Youth. College on Problems of Drug Dependence 73rd Annual Scientific Meeting, Palm Springs, CA, June 11, 2012.

141) Mariani JJ, Malcolm RJ, Glass A, Mamczur AK. Brady R, Nunes EV, Levin FR. Pilot trial of gabapentin for the treatment of benzodiazepine abuse or dependence in methadonemaintenance patients. College on Problems of Drug Dependence 73rd Annual Scientific Meeting, Palm Springs, CA, June 12, 2012.

142) Levin FR. Mariani JJ, Pavlicova M, Brooks DJ, Nunes EV, Agosti V, Bisaga A. Sullivan MA, Carpenter K. Venlafaxine treatment lowers abstinence rates in marijuana-dependent adults with depression. College on Problems of Drug Dependence 73rd Annual Scientific Meeting, Palm Springs, CA, June 12, 2012.

143) Talati A, Hasin DS, Endsley PE, Keyes KM, Wickramaratne PJ, Weissman MM, Levin FR. Smoking and psychopathology increasingly associated in more recent birth cohorts:

Implications for clinical & genetic studies. College on Problems of Drug Dependence 73rd Annual Scientific Meeting, Palm Springs, CA, June 12, 2012.

144) Murray A, Levin FR, Brooks DJ, Mariani JJ, Bisaga A, Xie A, Mamczur A, Glass A. Cotinine levels in non-cigarette-smoking marijuana blunt vs. joint users. College on Problems of Drug Dependence 73rd Annual Scientific Meeting, Palm Springs, CA, June 12, 2012.

145) Brooks DJ, Mahony A, Pavlicova M. Glass A. Levin FR. Identifying adult ADHD in adult marijuana treatment seekers. College on Problems of Drug Dependence 73rd Annual Scientific Meeting, Palm Springs, CA, June 13, 2012.

146) Stiles M. Evans SM, Glass A, Brooks DJ, Mahony A, Mariani JJ, Levin FR. Prevalence of early trauma in cannabis-dependent patients. College on Problems of Drug Dependence 73rd Annual Scientific Meeting, Palm Springs, CA, June 13, 2012.

147) Bisaga A, Sullivan MA, Glass A, Brooks DJ, Carpenter K, Mariani JJ, Levin FR. Nunes EV. A controlled trial of memantine as an adjunct to long-acting naltrexone for opioid dependence. College on Problems of Drug Dependence 73rd Annual Scientific Meeting, Palm Springs, CA, June 14, 2012.

148) Dakwar E, Levin FR, Foltin RW, Nunes EV, Hart CL. The effect of ketamine on use- related measures in cocaine-dependent volunteers. College on Problems of Drug Dependence 73rd Annual Scientific Meeting, Palm Springs, CA, June 14, 2012.

149) Carpenter KM, Kulesza M, Bond FW, Feder L, Levin FR, Nunes EV. An investigation of the structural and predictive validity of the AAQ-II among treatment seeking substance users. Association for Contextual Behavioral Science (ACBS), Washington, DC, July 22-25, 2012.

150) Luo SX, Covey L, Hu MC, Levin FR, Nunes EV. Predictive Modeling and Nonlinear Treatment Effects in a Multicenter, Randomized Controlled Trial of Methylphenidate in Smoke Cessation Intervention. American Academy of Addiction Psychiatry 23rd Annual Meeting, Aventura, FL, December 7, 2012.

151) David GP, Levin, FR, Want S, Blanco C. The Relationship Between Cannabis Use and Psychosis in a Nationally Representative Sample. American Academy of Addiction Psychiatry 23rd Annual Meeting, Aventura, FL, December 7, 2012.

152) Pavlicova M, Levin FR, Nunes E. Odd findings in the treatment of cannabis dependence plus depression: A placebo-controlled trial of venlafaxine. Psychiatric Research Annual Meeting, Park City, UT, February 6-9, 2013

153) Evans SM, Levin FR, Brooks DJ, Reed SC. Progesterone treatment for cocaine- dependent women: A pilot treatment trial. College on Problems of Drug Dependence 74th Annual Scientific Meeting, San Diego, CA, June 19, 2013.

154) Luo S, Covey K, Hu M, Levin FR, Nunes EV. Predictive modeling and nonlinear treatment effects in a multicenter, randomized controlled trial of methylphenidate for smoking cessation. College on Problems of Drug Dependence 74th Annual Scientific Meeting, San Diego, CA, June 19, 2013.

155) Luo S, Wall M, Covey L, Hu MC, Levin FR, Nunes EV. Modeling potential mechanisms of differential treatment effects in osmotic-release methylphenidate (OROSMPH) for smoking cessation. American Academy of Addiction Psychiatry 24th Annual Meeting, Scottsdale, AZ, December 7, 2013.

156) Kelly M, Glass A, Pavlicova M, Mariani JJ, Levin FR. Synthetic cannabinoid use among treatment seeking substance users. American Academy of Addiction Psychiatry 24th Annual Meeting, Scottsdale, AZ, December 7, 2013.

157) Levin FR. Pharmacologic Treatment of Attention-Deficit Hyperactivity Disorder in those with Substance Use Disorders, Presidential Symposium Chairs: Steven L. Batki, MD & Jeffrey Devido, MD at the American Psychiatric Association 167th Annual Meeting, New York, NY, May 4, 2014.

158) Levin FR. Choosing Treatment for Cannabis Use Disorders. In: Choosing the treatment for cannabis dependence, Chairs: Herbert D. Kleber, MD & Edward Nunes, MD at the American Psychiatric Association 167th Annual Meeting, New York, NY, May 6, 2014.

159) Levin FR. Medication Treatment for Cannabis Use Disorders. In: Advances in Addiction Psychopharmacology, Chairs: Domenic A. Ciraulo, MD and John A. Renner, Jr., MD at the American Psychiatric Association 167th Annual Meeting, New York, NY, May 7, 2014.

160) Levin FR. Mixed amphetamine salts-extended release for ADHD adults with cocaine use disorder. In: Focusing Attention on ADHD and Addiction, Chairs: Frances R. Levin, MD and Sonam O. Lasopa, MD at the College on Problem of Drug Dependence 76th Annual Scientific Meeting, San Juan, PR, June19, 2014.

161) Luo SX, Wall MM, Covey LS, Hu M. Levin FR, Nunes EV, Winbusen T. Modeling potential mechanisms of differential treatment effects in osmotic-release methylphenidate for smoking cessation. College on Problem of Drug Dependence 76th Annual Scientific Meeting, San Juan, PR, June 14-19, 2014.

162) Kelly MA, Mariani JJ, Glass A, Pavlicova M, Radin A, Levin FR. Synthetic cannabinoid use among treatment seeking substance users. College on Problem of Drug Dependence 76th Annual Scientific Meeting, San Juan, PR, June 14-19, 2014.

163) van de Glind G, van de Brink W, International Collaboration on ADHD and Substance Abuse (ICASA) Research Group, Levin FR. Results of the international ADHD in substance use disorder prevalence study. College on Problem of Drug Dependence 76th Annual Scientific Meeting, San Juan, PR, June 14-19, 2014.

164) Glass A, Mariani JJ, Pavlicova M, Nunes EV, Levin FR, Wall MM. Methods of pre-post analysis in the presence of missing data. College on Problem of Drug Dependence 76th Annual Scientific Meeting, San Juan, PR, June 14-19, 2014.

165) Evans E, Mishlen K, Glass A, Pavlicova M, Mariani JJ, Levin FR. Sullivan M. A comparison of young adults seeking treatment for cannabis and opioid dependence. College on Problem of Drug Dependence 76th Annual Scientific Meeting, San Juan, PR, June 14-19, 2014.162. Hien DA, Levin FR, Ruglass L, Lopez-Castro T. Enhancing the effects of cognitive behavioral therapy for PTSD and alcohol use disorders with

antidepressant medication: A randomized clinical trial. College on Problem of Drug Dependence 76th Annual Scientific Meeting, San Juan, PR, June 14-19, 2014.

166) Gonzalez R, Alicea A, Ginsberg Y, Gudjonsson G, Konstenius M, Levin FR. International rates of SUD and ADHD symptoms among prison inmates: Individual data and pooled effects. College on Problem of Drug Dependence 76th Annual Scientific Meeting, San Juan, PR, June 14-19, 2014.

167) Papini S. Hien DA, Neria Y. Levin FR. Role of the endogenous cannabinoid system in fear circuitry: Translational findings and clinical implications for post-traumatic stress disorder. College on Problem of Drug Dependence 76th Annual Scientific Meeting, San Juan, PR, June 14-19, 2014.

168) Vaughan B, Mariani JJ Pavlicova M, Glass A, Bisaga A, Nunes EV, Brooks DJ, Levin FR. Secondary analysis of smoking rates from a double-blind, placebo-controlled clinical trial of mixed-amphetamine salts and topiramate for cocaine dependence. College on Problem of Drug Dependence 76th Annual Scientific Meeting, San Juan, PR, June 14-19, 2014.

169) Sou B, Glass A. Brooks DJ, Mahony A, Mariani JJ, Grabowski J, Levin FR. Cigarette smoking trajectories among comorbid cocaine-dependent and attention deficit/hyperactivity-disorder individuals treated with extended-release mixed amphetamine salts. College on Problem of Drug Dependence 77th Annual Scientific Meeting, Phoenix, AZ, June 13-18, 2015.

170) Notzon D, Mariani JJ, Pavlicova M. Mixed-amphetamine salts increase abstinence from marijuana in patients with co-occurring attention-deficit/hyperactivity disorder and cocaine dependence. College on Problem of Drug Dependence 77th Annual Scientific Meeting, Phoenix, AZ, June 13-18, 2015.

171) Ford JH, Oliver KA, Cates-Wessel K, Giles M. Krahn D, Levin FR. The Impact of Performance in Practice on Physician Practice Improvements and Person Centered Care. 2015 AHRQ Research Conference, Crystal City, Virginia, October 4-6, 2015.

172) Ford JH, Oliver KA, Cates-Wessel K, Giles M. Krahn D, Levin FR. Performance in Practice: Impact on Physician Practice and Person Centered Care. Addiction Health Services Research (AHSR) Conference, Marina del Rey, California, October 14-16, 2015.